

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a cross-sectional study in the UK and Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027776
Article Type:	Research
Date Submitted by the Author:	15-Nov-2018
Complete List of Authors:	Shah, Karan; NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK, McGeechan, Kevin; The University of Sydney, School of Public Health; Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; NHMRC Clinical Trials Centre Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title: Health-related quality of life and wellbeing in people over 75 years of age with end-**  
4 **stage kidney disease managed with dialysis or comprehensive conservative care: a cross-**  
5 **sectional study in the UK and Australia**  
6  
7  
8  
9

10  
11  
12 **Karan Shah, Fliss E M Murtagh, Kevin McGeechan, Su Crail, Aine Burns, Anh D Tran,**  
13 **Rachael L Morton**  
14

- 15  
16  
17 1. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The  
18 University of Sydney, NSW, Australia  
19  
20  
21 2. Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull,  
22 UK  
23  
24  
25  
26 3. School of Public Health, The University of Sydney, NSW, Australia  
27  
28  
29 4. Royal Adelaide Hospital, SA, Australia  
30  
31 5. Royal Free Hospital, London NHS Foundation Trust, UK  
32  
33  
34

35 **Corresponding Author:**  
36

37 Karan Shah, MSc.  
38

39 Health Economics, NHMRC Clinical Trials Centre,  
40

41 The University of Sydney,  
42

43 92-94 Parramatta Road, Camperdown NSW 2050, Australia  
44  
45

46 Tel: +61 2 9562 5030  
47

48 Fax: +61 2 9562 5387  
49

50 Email: [karan.shah@ctc.usyd.edu.au](mailto:karan.shah@ctc.usyd.edu.au)  
51  
52  
53

54  
55  
56 **Word Count: 3358**  
57  
58  
59  
60

## ABSTRACT

### Objective

Decisions regarding treatment of older people with end-stage kidney disease need to be supported by information about the impact of dialysis on health-related quality of life (HRQoL) and wellbeing. Few data exist from patients aged 75 years of age or older.

### Design

Prospective cross-sectional study.

### Setting

3 renal units in the UK and Australia.

### Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration (eGFR)  $\leq 10$  ml/min/1.73m<sup>2</sup> and managed with comprehensive conservative, non-dialytic care.

### Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure—Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

### Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical component summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental component summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life due to burden (-28.59, 95%CI -41.77 to -15.42); symptoms (-5.93, 95%CI -14.61 to 2.73), and

1  
2  
3 effects of kidney disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O  
4  
5 wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation  
6  
7 between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 ( $p<0.001$ ),  
8  
9 but weak to moderate at domain level.  
10  
11

## 12 **Conclusions**

13  
14 Older people on dialysis report significantly higher burden and effects of kidney disease than  
15  
16 those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis  
17  
18 treatment, and should inform shared decision making about treatment options.  
19  
20

## 21 **Trial registration**

22  
23 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
24  
25 HREC/14/RAH/36).  
26  
27

## 28 **KEYWORDS**

29  
30 Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life,  
31  
32 Palliative Care  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

## INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged  $\geq 75$  years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could

1  
2  
3 be related to health and non-health factors that may impact the overall quality of life of a  
4 patient,[4]. Measures that look only at health in assessing the impact of these interventions  
5  
6 would be very likely to underestimate this impact,[3, 7].  
7  
8  
9

10  
11  
12 Dialysis has a large impact on the quality of life of both patients and their families; however,  
13 traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality  
14 of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects  
15 of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36™ is a short  
16 form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus  
17 disease-specific domains including the burden of kidney disease, symptoms/problems of  
18 kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures,  
19 often named wellbeing measures, could be used to capture more facets of peoples' lives than  
20 health status alone,[4].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 New instruments have been developed that provide information across health and social care,  
36 rather than just across health,[3]. The recently developed "Investigating Choice Experiments  
37 Capability Measure (ICECAP)" family of instruments have been designed to incorporate such  
38 dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work  
39 on the relationships between functioning and capability,[11, 12]. They seek to measure a  
40 conceptually different evaluative space through a focus on capabilities: that is, what a person  
41 is able to do and who they are able to be, rather than on functioning: what a person actually  
42 does and who they become,[13]. Capabilities refer to the potential to achieve certain states and  
43 perform certain actions,[4]. Having the capability to live life the way one desires is obviously  
44 important, also to older people, and reduction of this capability limits their wellbeing,[4, 14,  
45 15]. There is little research on how the ICECAP-O is related to other conceptualisations of  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 wellbeing, and the relationships between the ICECAP-O and measures of health (physical,  
4 psychological, and social) remain underexplored,[16].  
5  
6  
7  
8  
9

10 The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease  
11 quality of life using KDQOL-36™ questionnaire, and wellbeing using ICECAP-O  
12 questionnaire; to determine the association between treatment type and socio-demographic  
13 characteristics on these outcome measures; to assess the convergent validity between the  
14 ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess  
15 the feasibility and acceptability of questionnaires in older ESKD patients.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **MATERIALS AND METHODS**

### 27 *Study design*

28  
29 We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive  
30 conservative care in the UK and Australia between 2014 and 2017. The study was performed in  
31 accordance with the Australian National Statement on Ethical Conduct in Human Research (2007),  
32 and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of  
33 their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291)  
34 and Australia (R20140203 HREC/14/RAH/36). The study design conformed to the STROBE  
35 guidelines for observational studies (Item S1). Eligible subjects were fully informed about the  
36 purpose, benefits and risks of the study, and signed an approved participant consent form.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 *Setting and participants*

52 The study was undertaken at three renal units in the UK and Australia. Included were males  
53 and females aged  $\geq 75$  years with ESKD, managed with dialysis (facility hemodialysis, home  
54 hemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR)  
55  
56  
57  
58  
59  
60

1  
2  
3  $\leq 10\text{ml/min/1.73m}^2$  and managed with comprehensive conservative, non-dialytic care. The  
4  
5 exclusion criteria comprised cognitive impairment; patients unable to read English; and  
6  
7 patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in  
8  
9 each participating renal unit reviewed their clinic lists for all patients that met the eligibility  
10  
11 criteria.  
12  
13

### 14 15 16 17 ***Patient and public involvement***

18  
19 The research question was developed from prior qualitative work with people with end-stage  
20  
21 kidney disease and their carers,[17-19]. Patients were not directly involved in the design of this  
22  
23 research study. Patients and their caregivers were informed of the study and invited to  
24  
25 participate by the renal unit's research nurses. Participants were provided with an information  
26  
27 sheet and consent form for them to read. If they were interested in participating they were asked  
28  
29 to sign the consent form and then were provided with the surveys. Patients and their caregivers  
30  
31 were assured that participation was entirely voluntary, that they did not have to participate and  
32  
33 that their decision either way would not affect their clinical care.  
34  
35  
36  
37  
38  
39

### 40 41 ***Outcomes and variables***

42  
43 The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from  
44  
45 the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions.  
46  
47 Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility  
48  
49 instrument measured using the Pearson's correlation coefficient; and the feasibility and  
50  
51 acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and  
52  
53 specific items asking the patient whether the questionnaire was easy to complete, and whether  
54  
55 it covered questions important to their quality of life and wellbeing.  
56  
57  
58  
59  
60

### ***Data sources/measurement***

All eligible patients were invited to complete the KDQOL-36<sup>TM</sup> (Item S2) and the five-question ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic details such as age, sex, country, educational attainment, private health insurance and questions assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were collected (Item S4). Kidney treatment type (facility hemodialysis, home hemodialysis, peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on dialysis, and time of initiation) and renal transplant status were documented.

### ***Health related quality of life questionnaire***

The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[20]. The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as utilities, using a published SF-6D algorithm,[21]. The SF-6D is a generic preference-based single measure of health used to generate utilities from six domains: physical, role, social, pain, mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full health) scale, and were reported with mean and standard deviations (SDs) using UK population values,[21-23].

The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS (Mental Component Summary) scores, both of which are scored on a T-score metric (mean = 50, SD = 10, for the US general population),[20, 24]. The three kidney specific scales assess Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each of these scales is scored by transforming all items to a 0 to 100 possible range and averaging across the items on each scale to create scale scores,[20]. KDQOL-36 items are all scaled so that higher scores indicate better HRQoL,[20, 25].

### ***Wellbeing questionnaire***

The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing, including attachment (love and friendship); security (thinking about the future without concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure); and control (independence),[26]. It has four-level response options, representing four levels of capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full capability), and presented with mean and SDs using UK population weights,[3].

### ***Quantitative variables***

The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were treated as continuous, while patients' sex, treatment type (dialysis, conservative care), education (some high school or lower levels, completed high school or higher levels), private health insurance (yes, no), and health system (UK, Australia) were analysed as categorical variables. Age was also additionally dichotomised (less than or equal to, versus greater than the median age [81 years]).

### ***Statistical methods***

The analysis of data involved descriptive statistics assessing proportions and mean values of the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease, Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort. Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients' treatment type and socio-demographic characteristics. We hypothesised that HRQoL and wellbeing measures in each treatment group would be equivalent.

1  
2  
3 Linear regression with multivariable models was undertaken to determine the association  
4 between treatment type and patient characteristics on SF-6D utilities, KDQOL scores and  
5 ICECAP-O capability index. In the multivariable linear regression, age, sex, treatment type,  
6 education, private health insurance, and health system were included as covariates on the basis  
7 of *a priori* knowledge of their associations with the HRQoL and wellbeing measures.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-  
18 O wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall  
19 ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong  
20 positive correlations because both these instruments measures some similar facets of quality of  
21 life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and  
22 below 0.3 as weak,[16].  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Complete case analysis was performed for all outcomes. All statistical analyses were performed  
34 with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of <0.05 was considered  
35 statistically significant.  
36  
37  
38  
39  
40  
41  
42

## 43 **RESULTS**

44 A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%)  
45 patients managed with comprehensive conservative care. Overall, 65% were male, and the  
46 median age of the entire cohort was 81 years [IQR 75–78]. Patient characteristics are shown in  
47 Table 1.  
48  
49  
50  
51  
52  
53

### 54 ***Health-related quality of life SF-6D utilities***

55  
56  
57  
58  
59  
60

1  
2  
3 Of 129 patients, the mean utility for 116 patients with complete data was 0.62 (SD 0.14) (n =13  
4 missing values). The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65  
5 (SD 0.15) for the conservative care group (Table S1). The “vitality” domain reported the  
6 highest average score, and was responsible for the highest decrement in utilities in both  
7 treatment groups (Table S2).  
8  
9

10  
11  
12  
13  
14  
15  
16  
17 The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males (p = 0.006);  
18 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia  
19 (p = 0.03); and 0.07 (SD 0.14) lower for patients without a private health insurance compared  
20 to patients with a private health insurance (p = 0.03) (Table S1). When adjusted for all  
21 variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower  
22 CI = -0.14 and upper CI = -0.03, p = 0.002). There was no significant difference in the mean  
23 utilities observed between two treatments when adjusted for other variables (Table 2).  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **KDQOL scores**

37  
38 The mean KDQOL scores on the five domains for patients with complete data were as follows:  
39 PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of  
40 Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease  
41 score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD  
42 22.35).  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 In univariate analysis the PCS score was 5.46 points lower in females than males (p = 0.004)  
53 (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK  
54 patients (p = 0.03) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney  
55 Disease score was 28.12 points lower in the dialysis group than the conservative care group (p  
56  
57  
58  
59  
60

1  
2  
3 < 0.001) (indicating a higher burden of disease and lower quality of life); 14.06 points lower  
4  
5 in UK versus Australian patients (p = 0.01) (indicating higher burden of disease); 13.70 points  
6  
7 lower in patients without private health insurance compared to those with private health  
8  
9 insurance (p = 0.04) (indicating a higher burden of disease). The Effects of Kidney Disease  
10  
11 score was 17.11 points lower in the dialysis group compared to the conservative care group (p  
12  
13 < 0.001) (indicating higher effects of the disease and lower quality of life); 8.35 points lower  
14  
15 in UK versus Australian patients (p = 0.03) (indicating higher effects of the disease).  
16  
17  
18  
19  
20

21 The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better  
22  
23 mental health than the conservative care group. (Table S2).  
24  
25  
26  
27

28 When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale  
29  
30 was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on  
31  
32 conservative care (p<0.001) (Table 2, Figure 1). The mean score for Effects of Kidney Disease  
33  
34 when adjusted for all the other variables, was 16.49 lower (i.e. higher disease related effects)  
35  
36 for patients on dialysis compared with patients on comprehensive conservative care (p<0.001)  
37  
38 (Table 2, Figure 2). Adjusted scores were lower but not statistically, significantly different for  
39  
40 PCS, MCS and Symptoms of Kidney Disease between the two treatment groups.  
41  
42  
43  
44  
45  
46

#### 47 ***ICECAP-O capability index***

48 The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19)  
49  
50 (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and  
51  
52 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different.  
53  
54 Overall, the dialysis treatment group reported a lower wellbeing score on all five domains  
55  
56 compared to the conservative care group. The “attachment” domain showed the highest average  
57  
58  
59  
60

1  
2  
3 score, and was responsible for the highest contribution to capabilities in both treatment groups  
4  
5 (Table S2). When adjusted for other variables, there were no significant differences in the mean  
6  
7 capability index observed between the two treatments (Table 2).  
8  
9

### 10 11 12 ***Convergent validity*** 13

14 For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly  
15  
16 correlated with the overall ICECAP-O capability index with a Pearson's coefficient of 0.65  
17  
18 ( $p < 0.001$ ) and 0.56 ( $p < 0.001$ ) respectively. At the domain level, the role and control domains  
19  
20 of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D,  
21  
22 with a Pearson's coefficient of 0.51 ( $p < 0.001$ ) and 0.53 ( $p < 0.001$ ) respectively. All other  
23  
24 domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values  
25  
26 ranging from 0.02 to 0.49 (Table 3).  
27  
28  
29  
30  
31  
32

### 33 34 **Feasibility and acceptability** 35

36 115 of 129 patients completed the questionnaire, with 14 patients missing items for the  
37  
38 ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both  
39  
40 questionnaires easy to use and relevant to assessing their wellbeing. They responded with an  
41  
42 average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions  
43  
44 assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions  
45  
46 assessing the relevance of ICECAP-O and the SF-12 questions respectively.  
47  
48  
49  
50

## 51 52 **DISCUSSION** 53

54 This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores  
55  
56 and ICECAP-O capability index for patients with ESKD according to treatment, and socio-  
57  
58 demographic variables. Our findings suggest females compared with males, patients residing  
59  
60



1  
2  
3 in the UK compared with those residing in Australia, and patients without private health  
4 insurance compared with those with private health insurance have significantly lower SF-6D  
5 utilities. However, when adjusted for the other variables, only females reported significantly  
6 lower utilities compared with males. Furthermore, the study determined the convergent validity  
7 between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility  
8 and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with  
9 ESKD.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care  
22 group reflecting a potentially clinically meaningful difference related to treatment, however,  
23 this difference was not statistically significant. Meaningful differences or the minimal  
24 important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D  
25 utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[27]. It is therefore likely our  
26 study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O  
27 wellbeing for dialysis patients may also represent a clinically meaningful difference, however,  
28 MIDs for ICECAP-O have not yet been published.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 In our study, with the exception of a strong correlation between the “control” and “role”  
43 domain of the ICECAP-O with the “pain” domain on the SF-6D, most of the ICECAP-O  
44 domains were found to have weak to moderate correlations with the SF-6D corresponding  
45 domains. This indicates the newly developed capability instrument does measure different  
46 aspects of quality of life or wellbeing, and offers additional information when compared to  
47 measures of health, such as the SF-6D used in the conventional QALY approach. In addition,  
48 we observed a higher score for the feasibility and acceptability of the ICECAP-O questions  
49 indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There is debate in the health economics literature concerning the ways to apply the capability approach in economic evaluations with some suggesting that QALYs alone are adequate, while others argue this approach is too narrow, and that direct measures of capability or wellbeing provide a more extensive application of Sen's paradigm,[28]. Capability is empirically distinct from functioning and the content of capability instruments is not subsumed by the content of instruments used to capture changes in HRQoL for QALYs,[28].

Health economic analyses would benefit from the inclusion of individual capability measures; whether the focus should be only upon people's *achievements*—their “functioning”—or people's *capability to achieve* is contested,[28]. Sen's example of the fasting man versus the starving man serves as a key example for focusing on capability: two people, one of whom is starving and the other, who is fasting, have comparable functioning in terms of nourishment, but their capabilities to be nourished are notably different,[28]. The argument is that focusing on functioning alone would miss important distinctions, such as differences in freedom and choice between individuals,[28].

There are some limitations to this study. First, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed. Second, we did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing. Third, considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study. The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing. This

1  
2  
3 information is essential for doctors to discuss the relative benefits of dialysis compared with  
4  
5 conservative care.  
6  
7  
8  
9

10 In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD  
11 managed on dialysis compared to comprehensive conservative care. Furthermore, measuring  
12 wellbeing using a capability index provides additional insights into the impact of dialysis on  
13  
14 older people than HRQoL measurement alone and has potential to improve the economic  
15  
16 evaluation of treatment for ESKD.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

## Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

## Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

## Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

## Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the

1  
2  
3 UK. Each renal unit participating in the study obtained the approval of the Institutional Health  
4  
5 Research Ethics Committee to conduct the study. The study approval numbers are as follow:  
6  
7 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
8  
9 HREC/14/RAH/36).  
10  
11  
12  
13  
14

### 15 **Data sharing statement**

16  
17 Data for the study can be provided for specific research questions that are available from the  
18  
19 corresponding author on request  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. *Am J Kidney Dis*. 2012;59(3):419-27.
2. Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. *Clin J Am Soc Nephrol*. 2016;11(10):1909-14.
3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. *Soc Sci Med*. 2008;67(5):874-82.
4. Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. *PLoS One*. 2014;9(3):e92016.
5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. *Value Health*. 2009;12:S5-S9.
6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull*. 2010;96(1):5-21.
7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. *Hemodialysis International*. 2016;20(4):634-42.
8. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. *Nephrol Dial Transplant*. 2007;22(7):1955-62.
9. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care*. 1996;34(3):220-33.

10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. *Am J Kidney Dis.* 2016;67(6):820-1.
11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. *Soc Indic Res.* 1-16.
12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. *Qual Life Res.* 2012;21(1):167-76.
13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. *Soc Sci Med.* 2008;67(7):1190-8.
14. Sen A. *Choice, welfare, and measurement*: Harvard University Press; 1997.
15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? *Soc Sci Med.* 2006;62(8):1891-901.
16. Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. *Health Qual Life Outcomes.* 2013;11(1):57.
17. Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. *Am J Kidney Dis.* 2018;71(2):216-24.
18. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. *Nephrol Dial Transplant.* 2015;31(1):133-41.
19. Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. *Nephrol Dial Transplant.* 2011;26(12):4038-46.

- 1  
2  
3 20. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease  
4 quality of life 36-item short-form survey (KDQOL-36) in the United States. *Am J Kidney*  
5 *Dis.* 2018;71(4):461-8.  
6  
7
- 8  
9 21. Brazier JE, Roberts J. The estimation of a preference-based measure of health from  
10 the SF-12. *Med Care.* 2004;42(9):851-9.  
11  
12
- 13 22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of  
14 health from the SF-36. *J Health Econ.* 2002;21(2):271-92.  
15  
16
- 17 23. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference  
18 data using a nonparametric Bayesian method. *J Health Econ.* 2007;26(3):597-612.  
19  
20
- 21 24. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental  
22 health summary scales: Health Institute, New England Medical Center; 1995.  
23  
24
- 25 25. Hays R, Spritzer K. KDQOL-36™ Scoring Program (v1. 0). 2000.  
26  
27
- 28 26. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people  
29 using the ICEPOP CAPability (ICECAP-O) measure. *Appl Health Econ Health Policy.*  
30 2011;9(5):317-29.  
31  
32
- 33 27. Walters SJ, Brazier JE. Comparison of the minimally important difference for two  
34 health state utility measures: EQ-5D and SF-6D. *Qual Life Res.* 2005;14(6):1523-32.  
35  
36
- 37 28. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a  
38 Good Proxy Measure of Individual Capabilities? *Pharmacoeconomics.* 2017;35(6):637-46.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1: Patients characteristics according to treatment group**

Patient Characteristics	Dialysis	Conservative Care	Total
	n = 83 n (%)	n = 46 n (%)	n = 129 n (%)
<b>Dialysis</b>			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
<b>Median age (y)</b>	81 [78-84]	83 [81-87]	81 [78-85]
<b>Age group</b>			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
<b>Sex</b>			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
<b>Country</b>			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
<b>Education</b>			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
<b>Private Health Insurance</b>			
Yes	15 (18%)	14 (30%)	29 (22%)
No	65 (78%)	29 (63%)	94 (73%)
Unknown	1 (1%)	1 (2%)	2 (2%)

**Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)**

	Differences†	95 % Lower CI	95 % Upper CI	p value
<b>SF-6D utilities</b>	-0.05	-0.12	0.01	0.12
<b>KDQOL-PCS</b>	-3.17	-7.61	1.27	0.16
<b>KDQOL-MCS</b>	-2.41	-7.66	2.84	0.37
<b>KDQOL-Burden of Disease</b>	-28.59	-41.77	-15.42	<0.001*
<b>KDQOL-Symptoms of Disease</b>	-5.93	-14.61	2.73	0.18
<b>KDQOL-Effects of Disease</b>	-16.49	-25.98	-6.99	<0.001*
<b>ICECAP-O capability index</b>	-0.07	-0.16	0.02	0.12

† Difference in scores adjusted for age, gender, country, education, and health insurance status. \*  $p < 0.001$ , statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS -Mental Component Summary.

**Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)†  
using Pearson's correlation coefficient**

	ICECAP-O overall	ICECAP-O domain				
		Attachment	Security	Role	Enjoyment	Control
<b>SF-6D overall</b>	0.65**	-	-	-	-	-
<b>SF-6D domain</b>						
<b>Physical health</b>	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
<b>Role limitations</b>	0.30*	0.05	0.21*	0.28*	0.14	0.31*
<b>Social functioning</b>	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
<b>Pain</b>	<b>0.56**</b>	0.17	0.29*	<b>0.51**</b>	0.43**	<b>0.53**</b>
<b>Mental health</b>	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
<b>Vitality</b>	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

† Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). \* p < 0.05, statistical significance. \*\* p < 0.001, statistical significance.

## Figure Legends

**Figure 1-** *Title:* KDQOL-36 Burden of Kidney Disease score according to treatment group.

*Label:* (a) Dialysis group (n=83), (b) Conservative Care group (n=44).

*Explanatory text:* A higher score indicates lower burden of disease and better quality of life.

**Figure 2-** *Title:* KDQOL-36 Effects of Kidney Disease score according to treatment group.

*Label:* (a) Dialysis group (n=82), (b) Conservative Care group (n=45).

*Explanatory text:* A higher score indicates lower effects of disease and better quality of life.

1  
2  
3 **Supplementary Material**  
4  
5

6 **Supplementary Table 1 (Table S1):** SF-6D utilities, SF-12 PCS and MCS scores, and  
7  
8 ICECAP-O capability index according to patient characteristics  
9

10 **Supplementary Table 2 (Table S2):** Mean scores and weights of SF-6D, KDQOL-36 and  
11  
12 ICECAP-O according to treatment group  
13  
14

15 **Supplementary Table 3 (Table S3):** KDQOL-36 Burden of Kidney Disease, Symptoms of  
16  
17 Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics  
18  
19

20 **Supplementary Item 1 (Item S1):** STROBE Statement: checklist of items that should be  
21  
22 included in reports of observational studies  
23  
24


25 **Supplementary Item 2 (Item S2):** KDQOL-36 Questionnaire (SF-12: Questions 1 – 12  
26  
27 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden  
28  
29 of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms  
30  
31 of kidney disease: Questions 29 – 36)  
32  
33

34 **Supplementary Item 3 (Item S3):** ICECAP-O Questionnaire  
35


36 **Supplementary Item 4 (Item S4):** Background Questions  
37  
38

39 **Supplementary Item 5 (Item S5):** SF-6D domains  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1: KDQOL-36 Burden of Kidney Disease score according to treatment group.**




**(a) Dialysis group (n=83)**




**(b) Conservative Care group (n=44)**

**A higher score indicates lower burden of disease and better quality of life.**

**Figure 2: KDQOL-36 Effects of Kidney Disease score according to treatment group.**



**(a) Dialysis group (n=82)**



**(b) Conservative Care group (n=45)**

**A higher score indicates lower effects of disease and better quality of life.**

Characteristics	SF-6D (n = 116) <sup>†</sup>	PCS (n = 115) <sup>††</sup>	MCS (n = 115) <sup>‡</sup>	ICECAP-O (n = 126) <sup>‡‡</sup>
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
<b>Age</b>				
≤81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)
<b>Gender</b>				
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)
Females	0.58 (0.53-0.62)*	28.85 (26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)
<b>Treatment**</b>				
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)
<b>Country</b>				
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)
Australia	0.65 (0.61-0.69)*	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68-0.79)
<b>Education §</b>				
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76)
Completed high school or tertiary education	0.63 (0.58-0.69)	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)
<b>Private Health Insurance ¶</b>				
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)
No/Unknown	0.61 (0.58-0.64)*	32.25 (30.09-34.40)	46.77 (44.40-49.13)	0.71 (0.67-0.75)

<sup>†</sup> Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. <sup>††</sup> 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. <sup>‡</sup> 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. <sup>‡‡</sup> 3 out of 129 observations had missing values on SF-12 questionnaire and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 4 observations had missing values on ICECAP-O questionnaire and their capability index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Completed high school" and the responses to GCSEs/Completed high school/Diploma/A-level/Completed A-levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summary.



Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and ICECAP-O according to treatment group

Instrument	Score		Weights	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
<b>SF-6D</b> ‡				
Physical functioning	2.47 (1.04)	2.26 (0.68)	-0.02 (0.02)	-0.018 (0.02)
Role limitations	3.22 (1.44)	2.84 (1.28)	-0.06 (0.02)	-0.05 (0.03)
Social functioning	3.33 (1.62)	2.65 (1.25)	-0.06 (0.03)	-0.06 (0.03)
Pain	3.29 (2.13)	2.60 (1.37)	-0.05 (0.05)	-0.04 (0.05)
Mental health	2.90 (1.92)	2.33 (1.10)	-0.05 (0.04)	-0.05 (0.04)
Vitality	3.86 (1.72)	3.57 (1.13)	-0.09 (0.02)	-0.09 (0.01)
<b>KDQOL-36</b>				
Physical Component Summary (PCS)	31.22 (9.32)	34.32 (10.05)	-	-
Mental Component Summary (MCS)	47.67 (11.12)	46.56 (11.78)	-	-
Burden of Kidney Disease	34.71 (27.77)	62.83 (29.45)	-	-
Symptom of Kidney Disease	70.71 (18.74)	76.61 (19.18)	-	-
Effects of Kidney Disease	64.18 (20.27)	81.29 (21.92)	-	-
<b>ICECAP-O</b> ‡‡				
Attachment (love and friendship)	3.25 (0.87)	3.27 (0.81)	0.22 (0.06)	0.22 (0.05)
Security (thinking about future without concern)	2.42 (0.99)	2.71 (0.92)	0.09 (0.05)	0.10 (0.05)
Role (doing things that make you feel valued)	2.51 (0.82)	2.69 (0.85)	0.15 (0.04)	0.15 (0.05)
Enjoyment (enjoyment and pleasure)	2.52 (0.94)	2.80 (0.97)	0.13 (0.04)	0.14 (0.04)
Control (independence)	2.51 (0.94)	2.82 (1.01)	0.13 (0.08)	0.15 (0.09)

‡ 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score; 1 observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease score; 1 observation missing value on all ICECAP-O domains. ‡ SF-6D domain scores are weighted decrements. ‡‡ ICECAP-O domain scores are weighted increments. SD - Standard deviation. KDQOL-36 - Kidney disease quality of life with 36 items.

Characteristics	Burden of Kidney Disease (n = 127) <sup>†</sup>	Symptoms of Kidney Disease (n = 125) <sup>††</sup>	Effects of Kidney Disease (n = 127) <sup>‡</sup>
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
<b>Age</b>			
≤81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
<b>Gender</b>			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
<b>Treatment**</b>			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 (59.72-68.63)*
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
<b>Country</b>			
United Kingdom	37.81 (30.68-44.94)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
<b>Education§</b>			
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary education	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
<b>Private Health Insurance¶</b>			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)

<sup>†</sup> 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>††</sup> 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>‡</sup> 2 out of 129 observations had missing values on effects of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. KDOQI-36 - Kidney disease quality of life with 36 items.

**Supplementary Item 1 (Item S1): STROBE Statement:** checklist of items that should be included in reports of observational studies

	<b>Item No</b>	<b>Recommendation</b>	<b>Yes/No/NA</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes
Objectives	3	State specific objectives, including any pre-specified hypotheses	Yes
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes

Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes
Bias	9	Describe any efforts to address potential sources of bias	Yes
Study size	10	Explain how the study size was arrived at	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes
		(b) Describe any methods used to examine subgroups and interactions	Yes
		(c) Explain how missing data were addressed	Yes
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study— e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	No – screening logs at each site were not available
		(b) Give reasons for non-participation at each stage	No
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	Yes
		(b) Indicate number of participants with missing data for each variable of interest	Yes
		(c) <i>Cohort study</i> —Summarise follow-up time (e.g., average and total amount)	NA
Outcome data	15*	<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Yes
		(b) Report category boundaries when continuous variables were categorised	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Yes
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes

1  
2  
3 **Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12**  
4  
5 **(converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden**  
6  
7 **of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms**  
8  
9 **of kidney disease: Questions 29 – 36)**  
10  
11  
12  
13  
14  
15  
16  
17  
18

---

# Your Health – *and* – Well-Being

## **Kidney Disease and Quality of Life (KDQOL™-36)**

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 This survey asks for your views about your health. This information  
35 will help keep track of how you feel and how well you are able to do  
36 your usual activities.  
37  
38  
39



49 ***Thank you for completing these questions!***  
50  
51  
52  
53  
54  
55

---

56 Kidney Disease and Quality of Life™ (KDQOL™-36)  
57 English Version 1.  
58 Copyright © 2000 by RAND and the University of Arizona  
59  
60

# Your Health

**This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.**

- 1. In general, would you say your health is: [Mark an  in the one box that best describes your answer.]**

Excellent	Very good	Good	Fair	Poor
-----------	-----------	------	------	------

<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5
----------------------------	----------------------------	----------------------------	----------------------------	----------------------------

**The following items are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much? [Mark an  in a box on each line.]**

Yes, limited a lot	Yes, limited a little	No, not limited at all
--------------------------	-----------------------------	------------------------------

- 2. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf .....**  1.....  2.....  3
- 3. Climbing several flights of stairs .....**  1.....  2.....  3



1  
2  
3  
4 **During the past 4 weeks, have you had any of the following problems**  
5 **with your work or other regular daily activities as a result of your**  
6 **physical health?**  
7

8  
9 

Yes	No
-----	----

10  
11  
12  
13 4. Accomplished less than you would like.....  1..... 2

14  
15  
16 5. Were limited in the kind of work or other  
17 activities .....  1..... 2

18  
19  
20  
21  
22  
23 **During the past 4 weeks, have you had any of the following problems**  
24 **with your work or other regular daily activities as a result of any**  
25 **emotional problems (such as feeling depressed or anxious)?**  
26

27  
28 

Yes	No
-----	----

29  
30  
31  
32 6. Accomplished less than you would like.....  1..... 2

33  
34  
35 7. Didn't do work or other activities as carefully as  
36 usual .....  1..... 2

37  
38  
39  
40  
41  
42 **8. During the past 4 weeks, how much did pain interfere with your**  
43 **normal work (including both work outside the home and**  
44 **housework)?**  
45

46  
47 

Not at all	A little bit	Moderately	Quite a bit	Extremely
------------	--------------	------------	-------------	-----------

48  
49  
50  1       2       3       4       5

**These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please give the one answer that comes closest to the way you have been feeling.**

**How much of the time during the past 4 weeks ...**

			A good			
All	Most	bit	Some	A little	None	
of the	of the	of the	of the	of the	of the	of the
time	time	time	time	time	time	time

9. Have you felt calm and peaceful? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6
10. Did you have a lot of energy? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6
11. Have you felt downhearted and blue? ..  1 .....  2 .....  3 .....  4 .....  5 .....  6

**12. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)?**

All	Most	Some	A little	None
of the time	of the time	of the time	of the time	of the time
<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5

## Your Kidney Disease

How true or false is each of the following statements for you?

	Definitely true	Mostly true	Don't know	Mostly false	Definitely false
13. My kidney disease interferes too much with my life .....	<input type="checkbox"/> 1.....	<input type="checkbox"/> 2.....	<input type="checkbox"/> 3.....	<input type="checkbox"/> 4.....	<input type="checkbox"/> 5
14. Too much of my time is spent dealing with my kidney disease .....	<input type="checkbox"/> 1.....	<input type="checkbox"/> 2.....	<input type="checkbox"/> 3.....	<input type="checkbox"/> 4.....	<input type="checkbox"/> 5
15. I feel frustrated dealing with my kidney disease .....	<input type="checkbox"/> 1.....	<input type="checkbox"/> 2.....	<input type="checkbox"/> 3.....	<input type="checkbox"/> 4.....	<input type="checkbox"/> 5
16. I feel like a burden on my family .....	<input type="checkbox"/> 1.....	<input type="checkbox"/> 2.....	<input type="checkbox"/> 3.....	<input type="checkbox"/> 4.....	<input type="checkbox"/> 5

view only

**During the past 4 weeks, to what extent were you bothered by each of the following?**

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

- 17. Soreness in your muscles? .....  1 .....  2 .....  3 .....  4 .....  5
- 18. Chest pain? .....  1 .....  2 .....  3 .....  4 .....  5
- 19. Cramps? .....  1 .....  2 .....  3 .....  4 .....  5
- 20. Itchy skin? .....  1 .....  2 .....  3 .....  4 .....  5
- 21. Dry skin? .....  1 .....  2 .....  3 .....  4 .....  5
- 22. Shortness of breath? .....  1 .....  2 .....  3 .....  4 .....  5
- 23. Faintness or dizziness? .....  1 .....  2 .....  3 .....  4 .....  5
- 24. Lack of appetite? ...  1 .....  2 .....  3 .....  4 .....  5
- 25. Washed out or drained? .....  1 .....  2 .....  3 .....  4 .....  5
- 26. Numbness in hands or feet? .....  1 .....  2 .....  3 .....  4 .....  5
- 27. Nausea or upset stomach? .....  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>a</sup>. (Hemodialysis patient only)  
Problems with your access site? ...  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>b</sup>. (Peritoneal dialysis patient only)  
Problems with your catheter site?..  1 .....  2 .....  3 .....  4 .....  5

## Effects of Kidney Disease on Your Daily Life

Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease bother you in each of the following areas?

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 29.** Fluid restriction?.....  1 .....  2 .....  3 .....  4 .....  5
- 30.** Dietary restriction?.....  1 .....  2 .....  3 .....  4 .....  5
- 31.** Your ability to work around the house? .....  1 .....  2 .....  3 .....  4 .....  5
- 32.** Your ability to travel? .....  1 .....  2 .....  3 .....  4 .....  5
- 33.** Being dependent on doctors and other medical staff?.....  1 .....  2 .....  3 .....  4 .....  5
- 34.** Stress or worries caused by kidney disease? .....  1 .....  2 .....  3 .....  4 .....  5
- 35.** Your sex life? .....  1 .....  2 .....  3 .....  4 .....  5
- 36.** Your personal appearance? .....  1 .....  2 .....  3 .....  4 .....  5

**Supplementary Item 3 (Item S3): ICECAP-O Questionnaire**

**ABOUT YOUR QUALITY OF LIFE**

By placing a tick (✓) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.

**1. Love and Friendship**

I can have all of the love and friendship that I want	<input type="checkbox"/>	4
I can have a lot of the love and friendship that I want	<input type="checkbox"/>	3
I can have a little of the love and friendship that I want	<input type="checkbox"/>	2
I cannot have any of the love and friendship that I want	<input type="checkbox"/>	1

**2. Thinking about the future**

I can think about the future without any concern	<input type="checkbox"/>	4
I can think about the future with only a little concern	<input type="checkbox"/>	3
I can only think about the future with some concern	<input type="checkbox"/>	2
I can only think about the future with a lot of concern	<input type="checkbox"/>	1

**3. Doing things that make you feel valued**

I am able to do all of the things that make me feel valued	<input type="checkbox"/>	4
I am able to do many of the things that make me feel valued	<input type="checkbox"/>	3
I am able to do a few of the things that make me feel valued	<input type="checkbox"/>	2
I am unable to do any of the things that make me feel valued	<input type="checkbox"/>	1

**4. Enjoyment and pleasure**

I can have all of the enjoyment and pleasure that I want	<input type="checkbox"/>	4
I can have a lot of the enjoyment and pleasure that I want	<input type="checkbox"/>	3
I can have a little of the enjoyment and pleasure that I want	<input type="checkbox"/>	2
I cannot have any of the enjoyment and pleasure that I want	<input type="checkbox"/>	1

**5. Independence**

I am able to be completely independent	<input type="checkbox"/>	4
I am able to be independent in many things	<input type="checkbox"/>	3
I am able to be independent in a few things	<input type="checkbox"/>	2
I am unable to be at all independent	<input type="checkbox"/>	1

Tick  
one  
box  
only in  
each  
section

© Joanna Coast & Terry Flynn

**Supplementary Item 4 (Item S4): Background Questions**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Q1. What is your full name? \_\_\_\_\_
- Q2. What is your date of birth? \_\_\_\_\_ (dd/mm/yyyy)
- Q3. Gender (*please tick one*)
- Male
- Female
- Q4. What is your main residential postcode? \_\_\_\_\_
- Q5. What was your country of birth? \_\_\_\_\_
- Q6. What is the highest level of education you have completed? (*please tick the box that best describes you*)
- Primary school
- Some high school
- Completed high school
- Completed Diploma/ TAFE course
- Completed University Degree
- Q7. Do you have private health insurance? (*please tick one*)
- Yes
- No
- Don't know
- Q8. What type of kidney treatment are you **currently** having? (*please tick one*)
- Hemodialysis (satellite or hospital)
- Hemodialysis at home
- Peritoneal dialysis
- Non-dialysis renal supportive care

1  
2  
3 Q9. If you are currently on dialysis when did you first start dialysis?

4  
5 \_\_\_\_\_ (mm/yyyy)  
6

7  
8 Q10. Have you ever had a kidney transplant before? (*please tick one*)

9  
10 Yes  No

11  
12 Q11. The next two questions are about the **ICECAP-O survey**. On the scale below  
13  
14 please rate how easy this survey was to complete (*circle a number between 1*  
15  
16  
17 *and 5*)

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Q12. Did this survey measure the things that you consider important to your quality  
29  
30 of life? (*circle a number between 1 and 5*)

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42 Q13. If you responded with ‘somewhat disagree’ or ‘completely disagree,’ would  
43  
44 you like to tell us what you think the **ICECAP-O survey** was missing?

45  
46  
47 \_\_\_\_\_  
48  
49 \_\_\_\_\_  
50  
51 \_\_\_\_\_  
52  
53 \_\_\_\_\_  
54  
55 \_\_\_\_\_  
56  
57 \_\_\_\_\_  
58  
59  
60



1  
2  
3 Q14. The next two questions are about the **SF-12 survey**. On the scale below please rate  
4  
5 how easy this survey was to complete (*circle a number between 1 and 5*)  
6  
7

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

8  
9  
10  
11  
12  
13  
14  
15  
16  
17 Q15. Did this survey measure the things that you consider important to your quality  
18  
19 of life? (*circle a number between 1 and 5*)  
20  
21

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would  
32  
33 you like to tell us what you think the **SF-12 survey** was missing?  
34  
35

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---



---



---



---

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Supplementary Item 5 (Item S5): SF-6D domains

Level	SF-6D
	<i>Physical Functioning</i>
1	Your health does not limit you in <i>vigorous activities</i>
2	Your health limits you a little in <i>vigorous activities</i>
3	Your health limits you a little in <i>moderate activities</i>
4	Your health limits you a lot in <i>moderate activities</i>
5	Your health limits you <i>a little in bathing and dressing</i>
6	Your health limits you <i>a lot in bathing and dressing</i>
	<i>Role limitations</i>
1	You have <i>no</i> problems with your work or other regular daily activities as a result of your physical health or any emotional problems
2	You are limited in the kind of work or other activities as a result of your physical health
3	You accomplish less than you would like as a result of emotional problems
4	You are limited in the kind of work or other activities as a result of your physical health and accomplish less than you would like as a result of emotional problems
	<i>Social functioning</i>
1	Your health limits your social activities <i>none of the time</i>
2	Your health limits your social activities <i>a little of the time</i>
3	Your health limits your social activities <i>some of the time</i>
4	Your health limits your social activities <i>most of the time</i>
5	Your health limits your social activities <i>all of the time</i>
	<i>Pain</i>
1	You have <i>no</i> pain
2	You have pain but it does not interfere with your normal work (both outside the home and housework)
3	You have pain that interferes with your normal work (both outside the home and housework) <i>a little bit</i>
4	You have pain that interferes with your normal work (both outside the home and housework) <i>moderately</i>
5	You have pain that interferes with your normal work (both outside the home and housework) <i>quite a bit</i>
6	You have pain that interferes with your normal work (both outside the home and housework) <i>extremely</i>
	<i>Mental health</i>
1	You feel tense or downhearted and low <i>none of the time</i>
2	You feel tense or downhearted and low <i>a little of the time</i>
3	You feel tense or downhearted and low <i>some of the time</i>
4	You feel tense or downhearted and low <i>most of the time</i>
5	You feel tense or downhearted and low <i>all of the time</i>
	<i>Vitality</i>
1	You have a lot of energy <i>all of the time</i>
2	You have a lot of energy <i>most of the time</i>
3	You have a lot of energy <i>some of the time</i>
4	You have a lot of energy <i>a little of the time</i>
5	You have a lot of energy <i>none of the time</i>

Copyright © 2004 John Wiley & Sons, Ltd.

# BMJ Open

## Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a cross-sectional study in the UK and Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027776.R1
Article Type:	Research
Date Submitted by the Author:	26-Feb-2019
Complete List of Authors:	Shah, Karan; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK McGeechan, Kevin; The University of Sydney, School of Public Health Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics
<b>Primary Subject Heading</b>:	Health economics
Secondary Subject Heading:	Health services research, Qualitative research, Renal medicine, Research methods
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title: Health-related quality of life and wellbeing in people over 75 years of age with end-**  
4 **stage kidney disease managed with dialysis or comprehensive conservative care: a cross-**  
5 **sectional study in the UK and Australia**  
6  
7  
8  
9

10  
11  
12 **Karan Shah<sup>1</sup>, Fliss E M Murtagh<sup>2</sup>, Kevin McGeechan<sup>3</sup>, Su Crail<sup>4</sup>, Aine Burns<sup>5</sup>, Anh D**  
13 **Tran<sup>1</sup>, Rachael L Morton<sup>1</sup>**  
14

- 15  
16  
17 1. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The  
18 University of Sydney, NSW, Australia  
19  
20  
21 2. Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull,  
22 UK  
23  
24  
25  
26 3. School of Public Health, The University of Sydney, NSW, Australia  
27  
28  
29 4. Royal Adelaide Hospital, SA, Australia  
30  
31 5. Royal Free Hospital, London NHS Foundation Trust, UK  
32  
33  
34

35 **Corresponding Author:**  
36

37 Karan Shah, MSc.  
38

39 Health Economics, NHMRC Clinical Trials Centre,  
40

41 The University of Sydney,  
42

43 92-94 Parramatta Road, Camperdown NSW 2050, Australia  
44  
45

46 Tel: +61 2 9562 5030  
47

48 Fax: +61 2 9562 5387  
49

50 Email: [karan.shah@ctc.usyd.edu.au](mailto:karan.shah@ctc.usyd.edu.au)  
51  
52  
53  
54  
55

56 **Word Count: 3454**  
57  
58  
59  
60

## ABSTRACT

### Objective

Decisions regarding treatment of older people with end-stage kidney disease need to be supported by information about the impact of dialysis on health-related quality of life (HRQoL) and wellbeing. Few data exist from patients aged 75 years of age or older.

### Design

Prospective cross-sectional study.

### Setting

3 renal units in the UK and Australia.

### Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration (eGFR)  $\leq 10$  ml/min/1.73m<sup>2</sup> and managed with comprehensive conservative, non-dialytic care.

### Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure—Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

### Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical component summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental component summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life due to burden (-28.59, 95%CI -41.77 to -15.42); symptoms (-5.93, 95%CI -14.61 to 2.73), and

1  
2  
3 effects of kidney disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O  
4  
5 wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation  
6  
7 between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 ( $p<0.001$ ),  
8  
9 but weak to moderate at domain level.  
10  
11

## 12 **Conclusions**

13  
14 Older people on dialysis report significantly higher burden and effects of kidney disease than  
15  
16 those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis  
17  
18 treatment, and should inform shared decision making about treatment options.  
19  
20

## 21 **Trial registration**

22  
23 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
24  
25 HREC/14/RAH/36).  
26  
27

## 28 **KEYWORDS**

29  
30 Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life,  
31  
32 Palliative Care  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

## INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged  $\geq 75$  years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could



1  
2  
3 be related to health and non-health factors that may impact the overall quality of life of a  
4 patient,[4]. Measures that look only at health in assessing the impact of these interventions  
5  
6 would be very likely to underestimate this impact,[3, 7].  
7  
8  
9

10  
11  
12 Dialysis has a large impact on the quality of life of both patients and their families; however,  
13 traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality  
14 of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects  
15 of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36™ is a short  
16 form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus  
17 disease-specific domains including the burden of kidney disease, symptoms/problems of  
18 kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures,  
19 often named wellbeing measures, could be used to capture more facets of peoples' lives than  
20 health status alone,[4].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 New instruments have been developed that provide information across health and social care,  
36 rather than just across health,[3]. The recently developed "Investigating Choice Experiments  
37 Capability Measure (ICECAP)" family of instruments have been designed to incorporate such  
38 dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work  
39 on the relationships between functioning and capability,[11, 12]. They seek to measure a  
40 conceptually different evaluative space through a focus on capabilities: that is, what a person  
41 is able to do and who they are able to be, rather than on functioning: what a person actually  
42 does and who they become,[13]. Capabilities refer to the potential to achieve certain states and  
43 perform certain actions,[4]. Having the capability to live life the way one desires is obviously  
44 important, also to older people, and reduction of this capability limits their wellbeing,[4, 14,  
45 15]. The ICECAP-O instrument was specifically developed to measure capability in older  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 people. There is little research on how the ICECAP-O is related to other conceptualisations of  
4  
5 wellbeing, and the relationships between the ICECAP-O and measures of health (physical,  
6  
7 psychological, and social) remain underexplored,[16].  
8  
9

10  
11  
12 The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease  
13  
14 quality of life using KDQOL-36<sup>TM</sup> questionnaire, and wellbeing using ICECAP-O  
15  
16 questionnaire; to determine the association between treatment type and socio-demographic  
17  
18 characteristics on these outcome measures; to assess the convergent validity between the  
19  
20 ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess  
21  
22 the feasibility and acceptability of questionnaires in older ESKD patients.  
23  
24  
25  
26  
27

## 28 **MATERIALS AND METHODS**

### 29 *Study design*

30  
31 We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive  
32  
33 conservative care in the UK and Australia between 2014 and 2017. The study was performed in  
34  
35 accordance with the Australian National Statement on Ethical Conduct in Human Research (2007),  
36  
37 and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of  
38  
39 their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291)  
40  
41 and Australia (R20140203 HREC/14/RAH/36). The study design conformed to the STROBE  
42  
43 guidelines for observational studies (Item S1),[17]. Eligible subjects were fully informed about the  
44  
45 purpose, benefits and risks of the study, and signed an approved participant consent form.  
46  
47  
48  
49  
50  
51  
52  
53

### 54 *Setting and participants*

55  
56 The study was undertaken at three renal units in the UK and Australia. Included were males  
57  
58 and females aged  $\geq 75$  years with ESKD, managed with dialysis (facility hemodialysis, home  
59  
60

1  
2  
3 hemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR)  
4  $\leq 10 \text{ ml/min/1.73m}^2$  and managed with comprehensive conservative, non-dialytic care. The  
5  
6  
7 exclusion criteria comprised cognitive impairment; patients unable to read English; and  
8  
9  
10 patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in  
11  
12 each participating renal unit reviewed their clinic lists for all patients that met the eligibility  
13  
14  
15 criteria.

### 16 17 18 19 ***Patient and public involvement***

20  
21 The research question was developed from prior qualitative work with people with end-stage  
22  
23 kidney disease and their carers,[18-20]. Patients were not directly involved in the design of this  
24  
25 research study. Patients and their caregivers were informed of the study and invited to  
26  
27 participate by the renal unit's research nurses. Participants were provided with an information  
28  
29 sheet and consent form for them to read. If they were interested in participating they were asked  
30  
31 to sign the consent form and then were provided with two surveys contained in the one booklet,  
32  
33 (the ICECAP-O survey and the standard KDQOL-36<sup>TM</sup>) while at their renal clinic. Patients and  
34  
35 their caregivers were assured that participation was voluntary, that they did not have to  
36  
37 participate and that their decision either way would not affect their clinical care.  
38  
39  
40  
41  
42  
43  
44

### 45 ***Outcomes and variables***

46  
47 The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from  
48  
49 the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions.  
50  
51 Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility  
52  
53 instrument measured using the Pearson's correlation coefficient; and the feasibility and  
54  
55 acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and  
56  
57  
58  
59  
60

1  
2  
3 specific items asking the patient whether the questionnaire was easy to complete, and whether  
4  
5 it covered questions important to their quality of life and wellbeing.  
6  
7

### 8 9 10 ***Data sources/measurement***

11  
12 All eligible patients were invited to complete the KDQOL-36™ (Item S2) and the five-question  
13  
14 ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic  
15  
16 details such as age, sex, country, educational attainment, private health insurance and questions  
17  
18 assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were  
19  
20 collected (Item S4). Kidney treatment type (facility hemodialysis, home hemodialysis,  
21  
22 peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on  
23  
24 dialysis, and time of initiation) and renal transplant status were documented.  
25  
26  
27  
28

### 29 30 31 ***Health related quality of life questionnaire***

32  
33 The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[21].  
34  
35 The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as  
36  
37 utilities, using a published SF-6D algorithm,[22]. The SF-6D is a generic preference-based  
38  
39 single measure of health used to generate utilities from six domains: physical, role, social, pain,  
40  
41 mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full  
42  
43 health) scale, and were reported with mean and standard deviations (SDs) using UK population  
44  
45 values,[22-24].  
46  
47  
48  
49

50  
51 The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS  
52  
53 (Mental Component Summary) scores, both of which are scored on a T-score metric (mean =  
54  
55 50, SD = 10, for the US general population),[21, 25]. The three kidney specific scales assess  
56  
57 Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each  
58  
59  
60

1  
2  
3 of these scales is scored by transforming all items to a 0 to 100 possible range and averaging  
4 across the items on each scale to create scale scores,[21]. KDQOL-36 items are all scaled so  
5 that higher scores indicate better HRQoL,[21, 26].  
6  
7  
8  
9  
10

### 11 ***Wellbeing questionnaire***

12  
13  
14 The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing,  
15 including attachment (love and friendship); security (thinking about the future without  
16 concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure);  
17 and control (independence),[27]. It has four-level response options, representing four levels of  
18 capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were  
19 transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full  
20 capability), and presented with mean and SDs using UK population weights,[3].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 ***Quantitative variables***

34  
35 The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were  
36 treated as continuous, while patients' sex, treatment type (dialysis, conservative care),  
37 education (some high school or lower levels, completed high school or higher levels), private  
38 health insurance (yes, no), and health system (UK, Australia) were analysed as categorical  
39 variables. Age was also additionally dichotomised (less than or equal to, versus greater than  
40 the median age [81 years]).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 ***Statistical methods***

52  
53 The analysis of data involved descriptive statistics assessing proportions and mean values of  
54 the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease,  
55 Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort.  
56  
57  
58  
59  
60

1  
2  
3 Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean  
4 values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients'  
5 treatment type and socio-demographic characteristics. We hypothesised that HRQoL and  
6 wellbeing measures in each treatment group would be equivalent. Linear regression with  
7 multivariable models was undertaken to determine the association between treatment type and  
8 patient characteristics on SF-6D utilities, KDQOL scores and ICECAP-O capability index. In  
9 the multivariable linear regression, age, sex, treatment type, education, private health  
10 insurance, and health system were included as covariates on the basis of *a priori* knowledge of  
11 their associations with the HRQoL and wellbeing measures.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-O  
27 wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall  
28 ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong  
29 positive correlations because both these instruments measures some similar facets of quality of  
30 life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and  
31 below 0.3 as weak,[16].  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Complete case analysis was performed for all outcomes. All statistical analyses were performed  
43 with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of  $<0.05$  was considered  
44 statistically significant.  
45  
46  
47  
48  
49  
50

## 51 **RESULTS**

52 A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%)  
53 patients managed with comprehensive conservative care. Overall, 65% were male, and the  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 median age of the entire cohort was 81 years [IQR 75–78]. Patient characteristics are shown in  
4  
5 Table 1.  
6  
7  
8  
9

### 10 ***Health-related quality of life SF-6D utilities***

11  
12 Of 129 patients, the mean utility for 116 patients with complete data was 0.62 (SD 0.14) (n=13  
13  
14 missing values). The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65  
15  
16 (SD 0.15) for the conservative care group (Table S1). The “vitality” domain reported the  
17  
18 highest average score, and was responsible for the highest decrement in utilities in both  
19  
20 treatment groups (Table S2).  
21  
22  
23  
24  
25

26 The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males (p = 0.006);  
27  
28 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia  
29  
30 (p = 0.03); and 0.07 (SD 0.14) lower for patients without a private health insurance compared  
31  
32 to patients with a private health insurance (p = 0.03) (Table S1). When adjusted for all  
33  
34 variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower  
35  
36 CI = -0.14 and upper CI = -0.03, p = 0.002). There was no significant difference in the mean  
37  
38 utilities observed between two treatments when adjusted for other variables (Table 2).  
39  
40  
41  
42  
43  
44

### 45 **KDQOL scores**

46  
47 The mean KDQOL scores on the five domains for patients with complete data were as follows:  
48  
49 PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of  
50  
51 Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease  
52  
53 score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD  
54  
55 22.35).  
56  
57  
58  
59  
60

1  
2  
3 In univariate analysis the PCS score was 5.46 points lower in females than males ( $p = 0.004$ )  
4 (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK  
5 patients ( $p = 0.03$ ) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney  
6 Disease score was 28.12 points lower in the dialysis group than the conservative care group ( $p$   
7  $< 0.001$ ) (indicating a higher burden of disease and lower quality of life); 14.06 points lower  
8 in UK versus Australian patients ( $p = 0.01$ ) (indicating higher burden of disease); 13.70 points  
9 lower in patients without private health insurance compared to those with private health  
10 insurance ( $p = 0.04$ ) (indicating a higher burden of disease). The Effects of Kidney Disease  
11 score was 17.11 points lower in the dialysis group compared to the conservative care group ( $p$   
12  $< 0.001$ ) (indicating higher effects of the disease and lower quality of life); 8.35 points lower  
13 in UK versus Australian patients ( $p = 0.03$ ) (indicating higher effects of the disease).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better  
32 mental health than the conservative care group. (Table S2).  
33  
34  
35  
36  
37

38 When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale  
39 was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on  
40 conservative care ( $p < 0.001$ ) (Table 2, Figure 1 and Figure 2). The mean score for Effects of  
41 Kidney Disease when adjusted for all the other variables, was 16.49 lower (i.e. higher disease  
42 related effects) for patients on dialysis compared with patients on comprehensive conservative  
43 care ( $p < 0.001$ ) (Table 2, Figure 3 and 4). Adjusted scores were lower but not statistically,  
44 significantly different for PCS, MCS and Symptoms of Kidney Disease between the two  
45 treatment groups.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

### 58 *ICECAP-O capability index*

59  
60



1  
2  
3 The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19)  
4 (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and  
5  
6 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different.  
7  
8 Overall, the dialysis treatment group reported a lower wellbeing score on all five domains  
9  
10 compared to the conservative care group. The “attachment” domain showed the highest average  
11  
12 score, and was responsible for the highest contribution to capabilities in both treatment groups  
13  
14 (Table S2). When adjusted for other variables, there were no significant differences in the mean  
15  
16 capability index observed between the two treatments (Table 2).  
17  
18  
19  
20  
21  
22  
23

### 24 ***Convergent validity***

25  
26 For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly  
27  
28 correlated with the overall ICECAP-O capability index with a Pearson’s coefficient of 0.65  
29  
30 (p<0.001) and 0.56 (p<0.001) respectively. At the domain level, the role and control domains  
31  
32 of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D,  
33  
34 with a Pearson’s coefficient of 0.51 (p<0.001) and 0.53 (p<0.001) respectively. All other  
35  
36 domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values  
37  
38 ranging from 0.02 to 0.49 (Table 3).  
39  
40  
41  
42  
43  
44

### 45 **Feasibility and acceptability**

46  
47 115 of 129 patients completed the questionnaire, with 14 patients missing items for the  
48  
49 ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both  
50  
51 questionnaires easy to use and relevant to assessing their wellbeing. They responded with an  
52  
53 average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions  
54  
55 assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions  
56  
57 assessing the relevance of ICECAP-O and the SF-12 questions respectively.  
58  
59  
60

## DISCUSSION

This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores and ICECAP-O capability index for patients with ESKD according to treatment, and socio-demographic variables. Our findings suggest females compared with males, patients residing in the UK compared with those residing in Australia, and patients without private health insurance compared with those with private health insurance have significantly lower SF-6D utilities. However, when adjusted for the other variables, only females reported significantly lower utilities compared with males. Furthermore, the study determined the convergent validity between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with ESKD.

The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care group reflecting a potentially clinically meaningful difference related to treatment, however, this difference was not statistically significant. Meaningful differences or the minimal important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[28]. It is therefore likely our study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O wellbeing for dialysis patients may also represent a clinically meaningful difference, however, MIDs for ICECAP-O have not yet been published. Similarly, the KDQOL-36<sup>TM</sup> instrument identified a higher burden of disease, and greater effects of the disease for those on dialysis. This finding needs to be explored further in a larger sample size to investigate the potential detrimental effects of dialysis on HRQoL.

1  
2  
3 In our study, with the exception of a strong correlation between the “control” and “role”  
4 domain of the ICECAP-O with the “pain” domain on the SF-6D, most of the ICECAP-O  
5 domains were found to have weak to moderate correlations with the SF-6D corresponding  
6 domains. This indicates the newly developed capability instrument does measure different  
7 aspects of quality of life or wellbeing, and offers additional information when compared to  
8 measures of health, such as the SF-6D used in the conventional QALY approach. In addition,  
9 we observed a higher score for the feasibility and acceptability of the ICECAP-O questions  
10 indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 There is debate in the health economics literature concerning the ways to apply the capability  
25 approach in economic evaluations with some suggesting that QALYs alone are adequate, while  
26 others argue this approach is too narrow, and that direct measures of capability or wellbeing  
27 provide a more extensive application of Sen’s paradigm,[29]. Capability is empirically distinct  
28 from functioning and the content of capability instruments is not subsumed by the content of  
29 instruments used to capture changes in HRQoL for QALYs,[29].  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Health economic analyses would benefit from the inclusion of individual capability measures;  
41 whether the focus should be only upon people’s *achievements*—their “functioning”—or  
42 people’s *capability to achieve* is contested,[29]. Sen’s example of the fasting man versus the  
43 starving man serves as a key example for focusing on capability: two people, one of whom is  
44 starving and the other, who is fasting, have comparable functioning in terms of nourishment,  
45 but their capabilities to be nourished are notably different,[29]. The argument is that focusing  
46 on functioning alone would miss important distinctions, such as differences in freedom and  
47 choice between individuals,[29].  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 There are some limitations to this study. First, the sample size may not have been sufficient to  
4 detect a statistically significant difference in mean scores if one existed. Second, our  
5 observational study of older patients with end-stage kidney disease may not have perfectly  
6 matched the two groups with respect to co-morbid conditions. We did not have complete data  
7 on comorbidities and this may have impacted our ability to explore the associations between  
8 treatment type, HRQoL or wellbeing. Third, considering the cross-sectional nature of the data,  
9 we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time,  
10 which might be captured in a longitudinal study. The strengths of our study include a  
11 prospective assessment of HRQoL in people over 75 years of age, and the use of a novel  
12 measure to value wellbeing. This information is essential for doctors to discuss the relative  
13 benefits of dialysis compared with conservative care.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD  
32 managed on dialysis compared to comprehensive conservative care. Furthermore, measuring  
33 wellbeing using a capability index provides additional insights into the impact of dialysis on  
34 older people than HRQoL measurement alone and has potential to improve the economic  
35 evaluation of treatment for ESKD.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

## Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

## Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

## Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

## Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the

1  
2  
3 UK. Each renal unit participating in the study obtained the approval of the Institutional Health  
4  
5 Research Ethics Committee to conduct the study. The study approval numbers are as follow:  
6  
7 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
8  
9 HREC/14/RAH/36).  
10  
11  
12  
13  
14

#### 15 **Data sharing statement**

16  
17 Data for the study can be provided for specific research questions that are available from the  
18  
19 corresponding author on request  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. *Am J Kidney Dis.* 2012;59(3):419-27.
2. Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. *Clin J Am Soc Nephrol.* 2016;11(10):1909-14.
3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. *Soc Sci Med.* 2008;67(5):874-82.
4. Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. *PLoS One.* 2014;9(3):e92016.
5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. *Value Health.* 2009;12:S5-S9.
6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull.* 2010;96(1):5-21.
7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. *Hemodialysis International.* 2016;20(4):634-42.
8. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. *Nephrol Dial Transplant.* 2007;22(7):1955-62.
9. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care.* 1996;34(3):220-33.
10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. *Am J Kidney Dis.* 2016;67(6):820-1.
11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. *Soc Indic Res.* 1-16.
12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. *Qual Life Res.* 2012;21(1):167-76.
13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. *Soc Sci Med.* 2008;67(7):1190-8.
14. Sen A. Choice, welfare, and measurement: Harvard University Press; 1997.
15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? *Soc Sci Med.* 2006;62(8):1891-901.
16. Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. *Health Qual Life Outcomes.* 2013;11(1):57.
17. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLoS Med.* 2007;4(10):e297.
18. Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. *Am J Kidney Dis.* 2018;71(2):216-24.
19. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. *Nephrol Dial Transplant.* 2015;31(1):133-41.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. *Nephrol Dial Transplant*. 2011;26(12):4038-46.
21. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. *Am J Kidney Dis*. 2018;71(4):461-8.
22. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. *Med Care*. 2004;42(9):851-9.
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ*. 2002;21(2):271-92.
24. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. *J Health Econ*. 2007;26(3):597-612.
25. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental health summary scales: Health Institute, New England Medical Center; 1995.
26. Hays R, Spritzer K. KDQOL-36™ Scoring Program (v1. 0). 2000.
27. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. *Appl Health Econ Health Policy*. 2011;9(5):317-29.
28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res*. 2005;14(6):1523-32.
29. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? *Pharmacoeconomics*. 2017;35(6):637-46.



**Table 1: Patients characteristics according to treatment group**

Patient Characteristics	Dialysis	Conservative Care	Total
	n = 83 n (%)	n = 46 n (%)	n = 129 n (%)
<b>Dialysis</b>			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
<b>Median age (y)</b>	81 [78-84]	83 [81-87]	81 [78-85]
<b>Age group</b>			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
<b>Sex</b>			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
<b>Country</b>			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
<b>Education</b>			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
<b>Private Health Insurance</b>			
Yes	15 (18%)	14 (30%)	29 (22%)
No	65 (78%)	29 (63%)	94 (73%)
Unknown	1 (1%)	1 (2%)	2 (2%)

**Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)**

	Differences†	95 % Lower CI	95 % Upper CI	p value
<b>SF-6D utilities</b>	-0.05	-0.12	0.01	0.12
<b>KDQOL-PCS</b>	-3.17	-7.61	1.27	0.16
<b>KDQOL-MCS</b>	-2.41	-7.66	2.84	0.37
<b>KDQOL-Burden of Disease</b>	-28.59	-41.77	-15.42	<0.001*
<b>KDQOL-Symptoms of Disease</b>	-5.93	-14.61	2.73	0.18
<b>KDQOL-Effects of Disease</b>	-16.49	-25.98	-6.99	<0.001*
<b>ICECAP-O capability index</b>	-0.07	-0.16	0.02	0.12

† Difference in scores adjusted for age, gender, country, education, and health insurance status. \*  $p < 0.001$ , statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS -Mental Component Summary.

**Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)† using Pearson's correlation coefficient**

	ICECAP-O overall	ICECAP-O domain				
		Attachment	Security	Role	Enjoyment	Control
<b>SF-6D overall</b>	0.65**	-	-	-	-	-
<b>SF-6D domain</b>						
<b>Physical health</b>	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
<b>Role limitations</b>	0.30*	0.05	0.21*	0.28*	0.14	0.31*
<b>Social functioning</b>	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
<b>Pain</b>	<b>0.56**</b>	0.17	0.29*	<b>0.51**</b>	0.43**	<b>0.53**</b>
<b>Mental health</b>	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
<b>Vitality</b>	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

† Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). \* p < 0.05, statistical significance. \*\* p < 0.001, statistical significance.

## Figure Legends

**Figure 1-** *Title:* KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83).

*Explanatory text:* A higher score indicates lower burden of disease and better quality of life.

**Figure 2-** *Title:* KDQOL-36 Burden of Kidney Disease score Conservative Care group (n = 44).

*Explanatory text:* A higher score indicates lower burden of disease and better quality of life.

**Figure 3-** *Title:* KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82).

*Explanatory text:* A higher score indicates lower effects of disease and better quality of life.

**Figure 4-** *Title:* KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45).

*Explanatory text:* A higher score indicates lower effects of disease and better quality of life.

## Supplementary Material

**Supplementary Table 1 (Table S1):** SF-6D utilities, SF-12 PCS and MCS scores, and ICECAP-O capability index according to patient characteristics

**Supplementary Table 2 (Table S2):** Mean scores and weights of SF-6D, KDQOL-36 and ICECAP-O according to treatment group

**Supplementary Table 3 (Table S3):** KDQOL-36 Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics

**Supplementary Item 1 (Item S1):** STROBE Statement: checklist of items that should be included in reports of observational studies

**Supplementary Item 2 (Item S2):** KDQOL-36 Questionnaire (SF-12: Questions 1 – 12 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms of kidney disease: Questions 29 – 36)

**Supplementary Item 3 (Item S3):** ICECAP-O Questionnaire

**Supplementary Item 4 (Item S4):** Background Questions

**Supplementary Item 5 (Item S5):** SF-6D domains

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83). A higher score indicates lower burden of disease and better quality of life.

90x67mm (300 x 300 DPI)




Figure 2: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44). A higher score indicates lower burden of disease and better quality of life.

90x67mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3: KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82). A higher score indicates lower effects of disease and better quality of life.

90x67mm (300 x 300 DPI)






Figure 4: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45). A higher score indicates lower effects of disease and better quality of life.

90x67mm (300 x 300 DPI)

Characteristics	SF-6D (n = 116) <sup>†</sup> Mean (95% CI)	PCS (n = 115) <sup>††</sup> Mean (95% CI)	MCS (n = 115) <sup>‡</sup> Mean (95% CI)	ICECAP-O (n = 126) <sup>‡‡</sup> Mean (95% CI)
<b>Age</b>				
≤81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)
<b>Gender</b>				
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)
Females	0.58 (0.53-0.62)*	28.85 (26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)
<b>Treatment**</b>				
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)
<b>Country</b>				
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)
Australia	0.65 (0.61-0.69)*	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68-0.79)
<b>Education §</b>				
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76)
Completed high school or tertiary education	0.63 (0.58-0.69)	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)
<b>Private Health Insurance ¶</b>				
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)
No/Unknown	0.61 (0.58-0.64)*	32.25 (30.09-34.40)	46.77 (44.40-49.13)	0.71 (0.67-0.75)

<sup>†</sup> Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. <sup>††</sup> 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. <sup>‡</sup> 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. <sup>‡‡</sup> 3 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 4 observations had missing values on ICECAP-O questionnaire and their capability index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and ICECAP-O according to treatment group

Instrument	Score		Weights	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
<b>SF-6D</b> ‡				
Physical functioning	2.47 (1.04)	2.26 (0.68)	-0.02 (0.02)	-0.018 (0.02)
Role limitations	3.22 (1.44)	2.84 (1.28)	-0.06 (0.02)	-0.05 (0.03)
Social functioning	3.33 (1.62)	2.65 (1.25)	-0.06 (0.03)	-0.06 (0.03)
Pain	3.29 (2.13)	2.60 (1.37)	-0.05 (0.05)	-0.04 (0.05)
Mental health	2.90 (1.92)	2.33 (1.10)	-0.05 (0.04)	-0.05 (0.04)
Vitality	3.86 (1.72)	3.57 (1.13)	-0.09 (0.02)	-0.09 (0.01)
<b>KDQOL-36</b>				
Physical Component Summary (PCS)	31.22 (9.32)	34.32 (10.05)	-	-
Mental Component Summary (MCS)	47.67 (11.12)	46.56 (11.78)	-	-
Burden of Kidney Disease	34.71 (27.77)	62.83 (29.45)	-	-
Symptom of Kidney Disease	70.71 (18.74)	76.61 (19.18)	-	-
Effects of Kidney Disease	64.18 (20.27)	81.29 (21.92)	-	-
<b>ICECAP-O</b> ‡‡				
Attachment (love and friendship)	3.25 (0.87)	3.27 (0.81)	0.22 (0.06)	0.22 (0.05)
Security (thinking about future without concern)	2.42 (0.99)	2.71 (0.92)	0.09 (0.05)	0.10 (0.05)
Role (doing things that make you feel valued)	2.51 (0.82)	2.69 (0.85)	0.15 (0.04)	0.15 (0.05)
Enjoyment (enjoyment and pleasure)	2.52 (0.94)	2.80 (0.97)	0.13 (0.04)	0.14 (0.04)
Control (independence)	2.51 (0.94)	2.82 (1.01)	0.13 (0.08)	0.15 (0.09)

‡ 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score; 1 observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease score; 1 observation missing value on all ICECAP-O domains. ‡ SF-6D domain scores are weighted decrements. ‡‡ ICECAP-O domain scores are weighted increments. SD - Standard deviation. KDQOL-36 - Kidney disease quality of life with 36 items.

Characteristics	Burden of Kidney Disease (n = 127) <sup>†</sup>	Symptoms of Kidney Disease (n = 125) <sup>††</sup>	Effects of Kidney Disease (n = 127) <sup>‡</sup>
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
<b>Age</b>			
≤81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
<b>Gender</b>			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
<b>Treatment**</b>			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 (59.72-68.63)*
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
<b>Country</b>			
United Kingdom	37.81 (30.68-44.94)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
<b>Education§</b>			
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary education	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
<b>Private Health Insurance¶</b>			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)

<sup>†</sup> 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>††</sup> 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>‡</sup> 2 out of 129 observations had missing values on effects of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. KDOQI-36 - Kidney disease quality of life with 36 items.

**Supplementary Item 1 (Item S1): STROBE Statement:** checklist of items that should be included in reports of observational studies

	<b>Item No</b>	<b>Recommendation</b>	<b>Yes/No/NA, Page No.</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes, page 1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes, Page 2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes, Page 4-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	Yes, Page 7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Yes, Page 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes, Page 7-8
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes, Page 7-8

Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes, Page 8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes, Page 9-10
Bias	9	Describe any efforts to address potential sources of bias	Yes, Page 8
Study size	10	Explain how the study size was arrived at	Yes, Protocol Page 7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes, Page 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes, Page 10-11
		(b) Describe any methods used to examine subgroups and interactions	Yes, Page 10-11
		(c) Explain how missing data were addressed	Yes, Page 10-11
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA

		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study— e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	No – screening logs at each site were not available
		(b) Give reasons for non-participation at each stage	No
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	Yes, Page 7-8, 22
		(b) Indicate number of participants with missing data for each variable of interest	Yes, Page 12-14, 24
		(c) <i>Cohort study</i> —Summarise follow-up time (e.g., average and total amount)	NA
Outcome data	15*	<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes, Page 11-14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Yes, Page 11-14, 23- 24

		(b) Report category boundaries when continuous variables were categorised	Yes, Page 11-14, 23-24
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Yes, Page 11-14
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Yes, Page 15-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes, Page 17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes, Page 17
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes, Page 17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes, Page 18



1  
2  
3 **Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12**  
4 **(converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden**  
5 **of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms**  
6 **of kidney disease: Questions 29 – 36)**  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

# Your Health – and – Well-Being

## Kidney Disease and Quality of Life (KDQOL™-36)

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.



*Thank you for completing these questions!*

---

Kidney Disease and Quality of Life™ (KDQOL™-36)  
English Version 1.  
Copyright © 2000 by RAND and the University of Arizona

# Your Health

**This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.**

- 1. In general, would you say your health is: [Mark an  in the one box that best describes your answer.]**

Excellent	Very good	Good	Fair	Poor
<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5

**The following items are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much? [Mark an  in a box on each line.]**

Yes, limited a lot	Yes, limited a little	No, not limited at all
--------------------------	-----------------------------	------------------------------

- 2. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf .....**  1.....  2.....  3
- 3. Climbing several flights of stairs .....**  1.....  2.....  3

1  
2  
3  
4 **During the past 4 weeks, have you had any of the following problems**  
5 **with your work or other regular daily activities as a result of your**  
6 **physical health?**  
7

8  
9 

Yes	No
-----	----

10  
11  
12  
13 4. Accomplished less than you would like.....  1..... 2

14  
15  
16 5. Were limited in the kind of work or other  
17 activities .....  1..... 2

18  
19  
20  
21  
22  
23 **During the past 4 weeks, have you had any of the following problems**  
24 **with your work or other regular daily activities as a result of any**  
25 **emotional problems (such as feeling depressed or anxious)?**  
26

27 

Yes	No
-----	----

28  
29  
30  
31  
32 6. Accomplished less than you would like.....  1..... 2

33  
34  
35 7. Didn't do work or other activities as carefully as  
36 usual .....  1..... 2

37  
38  
39  
40  
41  
42 **8. During the past 4 weeks, how much did pain interfere with your**  
43 **normal work (including both work outside the home and**  
44 **housework)?**  
45

46 

Not at all	A little bit	Moderately	Quite a bit	Extremely
------------	--------------	------------	-------------	-----------

47  
48  
49  
50  1       2       3       4       5

1  
2  
3  
4 **These questions are about how you feel and how things have been with**  
5 **you during the past 4 weeks. For each question, please give the one**  
6 **answer that comes closest to the way you have been feeling.**  
7

8 **How much of the time during the past 4 weeks ...**  
9

		A good			
All	Most	bit	Some	A little	None
of the	of the	of the	of the	of the	of the
time	time	time	time	time	time

- 10  
11  
12  
13  
14  
15  
16  
17  
18  
19 **9.** Have you felt calm and  
20 peaceful? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6  
21  
22 **10.** Did you have a lot of  
23 energy? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6  
24  
25 **11.** Have you felt  
26 downhearted and blue? .  1 .....  2 .....  3 .....  4 .....  5 .....  6  
27  
28  
29  
30  
31  
32

- 33 **12. During the past 4 weeks, how much of the time has your physical**  
34 **health or emotional problems interfered with your social activities**  
35 **(like visiting with friends, relatives, etc.)?**  
36  
37

All	Most	Some	A little	None
of the time	of the time	of the time	of the time	of the time

38  
39  
40  
41  
42  1       2       3       4       5  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Your Kidney Disease

How true or false is each of the following statements for you?

Definitely true	Mostly true	Don't know	Mostly false	Definitely false
--------------------	----------------	---------------	-----------------	---------------------

- 13.** My kidney disease interferes too much with my life .....

1.....  2.....  3.....  4.....  5
- 14.** Too much of my time is spent dealing with my kidney disease .....

1.....  2.....  3.....  4.....  5
- 15.** I feel frustrated dealing with my kidney disease .....

1.....  2.....  3.....  4.....  5
- 16.** I feel like a burden on my family .....

1.....  2.....  3.....  4.....  5

view only

**During the past 4 weeks, to what extent were you bothered by each of the following?**

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

17. Soreness in your muscles? .....  1 .....  2 .....  3 .....  4 .....  5
18. Chest pain? .....  1 .....  2 .....  3 .....  4 .....  5
19. Cramps? .....  1 .....  2 .....  3 .....  4 .....  5
20. Itchy skin? .....  1 .....  2 .....  3 .....  4 .....  5
21. Dry skin? .....  1 .....  2 .....  3 .....  4 .....  5
22. Shortness of breath? .....  1 .....  2 .....  3 .....  4 .....  5
23. Faintness or dizziness? .....  1 .....  2 .....  3 .....  4 .....  5
24. Lack of appetite? ...  1 .....  2 .....  3 .....  4 .....  5
25. Washed out or drained? .....  1 .....  2 .....  3 .....  4 .....  5
26. Numbness in hands or feet? .....  1 .....  2 .....  3 .....  4 .....  5
27. Nausea or upset stomach? .....  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>a</sup>. (Hemodialysis patient only)  
Problems with your access site? ...  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>b</sup>. (Peritoneal dialysis patient only)  
Problems with your catheter site?..  1 .....  2 .....  3 .....  4 .....  5

## Effects of Kidney Disease on Your Daily Life

**Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease bother you in each of the following areas?**

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

- |   |                            |       |                            |       |                            |       |                            |       |                            |
|---|----------------------------|-------|----------------------------|-------|----------------------------|-------|----------------------------|-------|----------------------------|
| <b>29.</b> Fluid restriction?....                                   | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>30.</b> Dietary restriction?.                                    | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>31.</b> Your ability to work around the house? .....             | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>32.</b> Your ability to travel? .....                            | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>33.</b> Being dependent on doctors and other medical staff?..... | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>34.</b> Stress or worries caused by kidney disease? .....        | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>35.</b> Your sex life? .....                                     | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |
| <b>36.</b> Your personal appearance? .....                          | <input type="checkbox"/> 1 | ..... | <input type="checkbox"/> 2 | ..... | <input type="checkbox"/> 3 | ..... | <input type="checkbox"/> 4 | ..... | <input type="checkbox"/> 5 |

### Supplementary Item 3 (Item S3): ICECAP-O Questionnaire

#### ABOUT YOUR QUALITY OF LIFE

By placing a tick (✓) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.

##### 1. Love and Friendship

- |  |                          |   |
|--|--------------------------|---|
| I can have all of the love and friendship that I want      | <input type="checkbox"/> | 4 |
| I can have a lot of the love and friendship that I want    | <input type="checkbox"/> | 3 |
| I can have a little of the love and friendship that I want | <input type="checkbox"/> | 2 |
| I cannot have any of the love and friendship that I want   | <input type="checkbox"/> | 1 |

##### 2. Thinking about the future

- |   |                          |   |
|---|--------------------------|---|
| I can think about the future without any concern        | <input type="checkbox"/> | 4 |
| I can think about the future with only a little concern | <input type="checkbox"/> | 3 |
| I can only think about the future with some concern     | <input type="checkbox"/> | 2 |
| I can only think about the future with a lot of concern | <input type="checkbox"/> | 1 |

##### 3. Doing things that make you feel valued

- |  |                          |   |
|--|--------------------------|---|
| I am able to do all of the things that make me feel valued   | <input type="checkbox"/> | 4 |
| I am able to do many of the things that make me feel valued  | <input type="checkbox"/> | 3 |
| I am able to do a few of the things that make me feel valued | <input type="checkbox"/> | 2 |
| I am unable to do any of the things that make me feel valued | <input type="checkbox"/> | 1 |

##### 4. Enjoyment and pleasure

- |   |                          |   |
|---|--------------------------|---|
| I can have all of the enjoyment and pleasure that I want      | <input type="checkbox"/> | 4 |
| I can have a lot of the enjoyment and pleasure that I want    | <input type="checkbox"/> | 3 |
| I can have a little of the enjoyment and pleasure that I want | <input type="checkbox"/> | 2 |
| I cannot have any of the enjoyment and pleasure that I want   | <input type="checkbox"/> | 1 |

##### 5. Independence

- |   |                          |   |
|---|--------------------------|---|
| I am able to be completely independent      | <input type="checkbox"/> | 4 |
| I am able to be independent in many things  | <input type="checkbox"/> | 3 |
| I am able to be independent in a few things | <input type="checkbox"/> | 2 |
| I am unable to be at all independent        | <input type="checkbox"/> | 1 |

Tick  
one  
box  
only in  
each  
section

© Joanna Coast & Terry Flynn



**Supplementary Item 4 (Item S4): Background Questions**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Q1. What is your full name? \_\_\_\_\_
- Q2. What is your date of birth? \_\_\_\_\_ (dd/mm/yyyy)
- Q3. Gender (*please tick one*)
- Male
- Female
- Q4. What is your main residential postcode? \_\_\_\_\_
- Q5. What was your country of birth? \_\_\_\_\_
- Q6. What is the highest level of education you have completed? (*please tick the box that best describes you*)
- Primary school
- Some high school
- Completed high school
- Completed Diploma/ TAFE course
- Completed University Degree
- Q7. Do you have private health insurance? (*please tick one*)
- Yes
- No
- Don't know
- Q8. What type of kidney treatment are you **currently** having? (*please tick one*)
- Hemodialysis (satellite or hospital)
- Hemodialysis at home
- Peritoneal dialysis
- Non-dialysis renal supportive care

1  
2  
3 Q9. If you are currently on dialysis when did you first start dialysis?

4  
5 \_\_\_\_\_ (mm/yyyy)  
6

7  
8 Q10. Have you ever had a kidney transplant before? (*please tick one*)

9  
10 Yes  No

11  
12 Q11. The next two questions are about the **ICECAP-O survey**. On the scale below  
13  
14 please rate how easy this survey was to complete (*circle a number between 1*  
15  
16  
17 *and 5*)

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 Q12. Did this survey measure the things that you consider important to your quality  
29  
30 of life? (*circle a number between 1 and 5*)

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42 Q13. If you responded with 'somewhat disagree' or 'completely disagree,' would  
43  
44 you like to tell us what you think the **ICECAP-O survey** was missing?

45  
46  
47 \_\_\_\_\_  
48  
49 \_\_\_\_\_  
50  
51 \_\_\_\_\_  
52  
53 \_\_\_\_\_  
54  
55 \_\_\_\_\_  
56  
57 \_\_\_\_\_  
58  
59  
60

Q14. The next two questions are about the **SF-12 survey**. On the scale below please rate how easy this survey was to complete (*circle a number between 1 and 5*)

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

Q15. Did this survey measure the things that you consider important to your quality of life? (*circle a number between 1 and 5*)

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would you like to tell us what you think the **SF-12 survey** was missing?

---



---



---



---

1  
2  
3 **Supplementary Item 5 (Item S5): SF-6D domains**  
4  
5  
6  
7  
8  
9  
10  
11  
12

Level	SF-6D
	<i>Physical Functioning</i>
1	Your health does not limit you in <i>vigorous activities</i>
2	Your health limits you a little in <i>vigorous activities</i>
3	Your health limits you a little in <i>moderate activities</i>
4	Your health limits you a lot in <i>moderate activities</i>
5	Your health limits you <i>a little in bathing and dressing</i>
6	Your health limits you <i>a lot in bathing and dressing</i>
	<i>Role limitations</i>
1	You have <i>no</i> problems with your work or other regular daily activities as a result of your physical health or any emotional problems
2	You are limited in the kind of work or other activities as a result of your physical health
3	You accomplish less than you would like as a result of emotional problems
4	You are limited in the kind of work or other activities as a result of your physical health and accomplish less than you would like as a result of emotional problems
	<i>Social functioning</i>
1	Your health limits your social activities <i>none of the time</i>
2	Your health limits your social activities <i>a little of the time</i>
3	Your health limits your social activities <i>some of the time</i>
4	Your health limits your social activities <i>most of the time</i>
5	Your health limits your social activities <i>all of the time</i>
	<i>Pain</i>
1	You have <i>no</i> pain
2	You have pain but it does not interfere with your normal work (both outside the home and housework)
3	You have pain that interferes with your normal work (both outside the home and housework) <i>a little bit</i>
4	You have pain that interferes with your normal work (both outside the home and housework) <i>moderately</i>
5	You have pain that interferes with your normal work (both outside the home and housework) <i>quite a bit</i>
6	You have pain that interferes with your normal work (both outside the home and housework) <i>extremely</i>
	<i>Mental health</i>
1	You feel tense or downhearted and low <i>none of the time</i>
2	You feel tense or downhearted and low <i>a little of the time</i>
3	You feel tense or downhearted and low <i>some of the time</i>
4	You feel tense or downhearted and low <i>most of the time</i>
5	You feel tense or downhearted and low <i>all of the time</i>
	<i>Vitality</i>
1	You have a lot of energy <i>all of the time</i>
2	You have a lot of energy <i>most of the time</i>
3	You have a lot of energy <i>some of the time</i>
4	You have a lot of energy <i>a little of the time</i>
5	You have a lot of energy <i>none of the time</i>

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Copyright © 2004 John Wiley & Sons, Ltd.

# BMJ Open

## Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a cross-sectional study in the UK and Australia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027776.R2
Article Type:	Research
Date Submitted by the Author:	08-Apr-2019
Complete List of Authors:	Shah, Karan; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK McGeechan, Kevin; The University of Sydney, School of Public Health Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics
<b>Primary Subject Heading</b>:	Health economics
Secondary Subject Heading:	Health services research, Qualitative research, Renal medicine, Research methods
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life

SCHOLARONE™  
Manuscripts

1  
2  
3 **Title: Health-related quality of life and wellbeing in people over 75 years of age with end-**  
4 **stage kidney disease managed with dialysis or comprehensive conservative care: a cross-**  
5 **sectional study in the UK and Australia**  
6  
7  
8  
9

10  
11  
12 **Karan K Shah<sup>1</sup>, Fliss E M Murtagh<sup>2</sup>, Kevin McGeechan<sup>3</sup>, Su Crail<sup>4</sup>, Aine Burns<sup>5</sup>, Anh D**  
13 **Tran<sup>1</sup>, Rachael L Morton<sup>1</sup>**  
14

- 15  
16  
17 1. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The  
18 University of Sydney, NSW, Australia  
19  
20  
21 2. Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull,  
22 UK  
23  
24  
25  
26 3. School of Public Health, The University of Sydney, NSW, Australia  
27  
28  
29 4. Royal Adelaide Hospital, SA, Australia  
30  
31 5. Royal Free Hospital, London NHS Foundation Trust, UK  
32  
33  
34

35 **Corresponding Author:**  
36

37 Karan K Shah, MSc.  
38

39 Health Economics, NHMRC Clinical Trials Centre,  
40

41 The University of Sydney,  
42

43 92-94 Parramatta Road, Camperdown NSW 2050, Australia  
44  
45

46 Tel: +61 2 9562 5030  
47

48 Fax: +61 2 9562 5387  
49

50 Email: [karan.shah@ctc.usyd.edu.au](mailto:karan.shah@ctc.usyd.edu.au)  
51  
52  
53  
54  
55

56 **Word Count: 3550**  
57  
58  
59  
60

## ABSTRACT

### Objective

To measure HRQoL and wellbeing in older people with end stage kidney disease and to determine the association between treatment type and socio-demographic characteristics on these outcome measures. In addition, to assess the convergent validity between the HRQoL and wellbeing measure and their feasibility and acceptability in this population.

### Design

Prospective cross-sectional study.

### Setting

3 renal units in the UK and Australia.

### Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration (eGFR)  $\leq 10$  ml/min/1.73m<sup>2</sup> and managed with comprehensive conservative, non-dialytic care.

### Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure–Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

### Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical Component Summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental Component Summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life

1  
2  
3 due to Burden (-28.59, 95%CI -41.77 to -15.42); Symptoms (-5.93, 95%CI -14.61 to 2.73), and  
4  
5 Effects of Kidney Disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O  
6  
7 wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation  
8  
9 between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 ( $p<0.001$ ),  
10  
11 but weak to moderate at domain level.  
12  
13

## 14 **Conclusions**

15  
16 Older people on dialysis report significantly higher burden and effects of kidney disease than  
17  
18 those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis  
19  
20 treatment, and should inform shared decision making about treatment options.  
21  
22

## 23 **Trial registration**

24  
25 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
26  
27 HREC/14/RAH/36).  
28  
29

## 30 **KEYWORDS**

31  
32 Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life,  
33  
34 Palliative Care  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

## INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged  $\geq 75$  years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could

1  
2  
3 be related to health and non-health factors that may impact the overall quality of life of a  
4 patient,[4]. Measures that look only at health in assessing the impact of these interventions  
5  
6 would be very likely to underestimate this impact,[3, 7].  
7  
8  
9

10  
11  
12 Dialysis has a large impact on the quality of life of both patients and their families; however,  
13 traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality  
14 of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects  
15 of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36™ is a short  
16 form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus  
17 disease-specific domains including the burden of kidney disease, symptoms/problems of  
18 kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures,  
19 often named wellbeing measures, could be used to capture more facets of peoples' lives than  
20 health status alone,[4].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 New instruments have been developed that provide information across health and social care,  
36 rather than just across health,[3]. The recently developed "Investigating Choice Experiments  
37 Capability Measure (ICECAP)" family of instruments have been designed to incorporate such  
38 dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work  
39 on the relationships between functioning and capability,[11, 12]. They seek to measure a  
40 conceptually different evaluative space through a focus on capabilities: that is, what a person  
41 is able to do and who they are able to be, rather than on functioning: what a person actually  
42 does and who they become,[13]. Capabilities refer to the potential to achieve certain states and  
43 perform certain actions,[4]. Having the capability to live life the way one desires is obviously  
44 important, also to older people, and reduction of this capability limits their wellbeing,[4, 14,  
45 15]. The ICECAP-O instrument was specifically developed to measure capability in older  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 people. There is little research on how the ICECAP-O is related to other conceptualisations of  
4  
5 wellbeing, and the relationships between the ICECAP-O and measures of health (physical,  
6  
7 psychological, and social) remain underexplored,[16].  
8  
9

10  
11  
12 The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease  
13  
14 quality of life using KDQOL-36<sup>TM</sup> questionnaire, and wellbeing using ICECAP-O  
15  
16 questionnaire; to determine the association between treatment type and socio-demographic  
17  
18 characteristics on these outcome measures; to assess the convergent validity between the  
19  
20 ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess  
21  
22 the feasibility and acceptability of questionnaires in older ESKD patients.  
23  
24  
25  
26  
27

## 28 **MATERIALS AND METHODS**

### 29 *Study design*

30  
31 We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive  
32  
33 conservative care in the UK and Australia between 2014 and 2017. The study was performed in  
34  
35 accordance with the Australian National Statement on Ethical Conduct in Human Research (2007),  
36  
37 and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of  
38  
39 their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291)  
40  
41 and Australia (R20140203 HREC/14/RAH/36). The study was reported using STROBE guidelines  
42  
43 for observational studies (Item S1),[17]. Eligible subjects were fully informed about the purpose,  
44  
45 benefits and risks of the study, and signed an approved participant consent form.  
46  
47  
48  
49  
50  
51

### 52 *Setting and participants*

53  
54 The study was undertaken at three renal units in the UK and Australia. Included were males  
55  
56 and females aged  $\geq 75$  years with ESKD, managed with dialysis (facility haemodialysis, home  
57  
58  
59  
60

1  
2  
3 haemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR)  
4  $\leq 10\text{ml}/\text{min}/1.73\text{m}^2$  and managed with comprehensive conservative, non-dialytic care. The  
5  
6 exclusion criteria comprised cognitive impairment; patients unable to read English; and  
7  
8 patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in  
9  
10 each participating renal unit reviewed their clinic lists for all patients that met the eligibility  
11  
12 criteria.  
13  
14  
15

### 16 17 18 19 ***Sample size calculation***

20  
21 As per the study protocol, a sample size of 194 patients (97 on dialysis, 97 on comprehensive  
22  
23 conservative care) was calculated to detect a mean difference of 0.05 in the outcomes with 80%  
24  
25 power and 95% confidence.  
26  
27  
28

### 29 30 31 ***Patient and public involvement***

32  
33 The research question was developed from prior qualitative work with people with end-stage  
34  
35 kidney disease and their carers,[18-20]. Patients were not directly involved in the design of this  
36  
37 research study. Patients and their caregivers were informed of the study and invited to  
38  
39 participate by the renal unit's research nurses. Participants were provided with an information  
40  
41 sheet and consent form for them to read. If they were interested in participating they were asked  
42  
43 to sign the consent form and then were provided with two surveys contained in the one booklet,  
44  
45 (the ICECAP-O survey and the standard KDQOL-36<sup>TM</sup>) while at their renal clinic. Patients and  
46  
47 their caregivers were assured that participation was voluntary, that they did not have to  
48  
49 participate and that their decision either way would not affect their clinical care.  
50  
51  
52  
53

### 54 55 56 ***Outcomes and variables***

1  
2  
3 The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from  
4 the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions.  
5  
6 Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility  
7 instrument measured using the Pearson's correlation coefficient; and the feasibility and  
8 acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and  
9 specific items asking the patient whether the questionnaire was easy to complete, and whether  
10 it covered questions important to their quality of life and wellbeing.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 ***Data sources/measurement***

23  
24 All eligible patients were invited to complete the KDQOL-36<sup>TM</sup> (Item S2) and the five-question  
25 ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic  
26 details such as age, sex, country, educational attainment, private health insurance and questions  
27 assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were  
28 collected (Item S4). Kidney treatment type (facility haemodialysis, home haemodialysis,  
29 peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on  
30 dialysis, and time of initiation) and renal transplant status were documented.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 ***Health related quality of life questionnaire***

43  
44 The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[21].  
45  
46 The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as  
47 utilities, using a published SF-6D algorithm,[22]. The SF-6D is a generic preference-based  
48 single measure of health used to generate utilities from six domains: physical, role, social, pain,  
49 mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full  
50 health) scale, and were reported with mean and standard deviations (SDs) using UK population  
51 values,[22-24].  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS  
6 (Mental Component Summary) scores, both of which are scored on a T-score metric (mean =  
7 50, SD = 10, for the US general population),[21, 25]. The three kidney specific scales assess  
8 Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each  
9 of these scales is scored by transforming all items to a 0 to 100 possible range and averaging  
10 across the items on each scale to create scale scores,[21]. KDQOL-36 items are all scaled so  
11 that higher scores indicate better HRQoL,[21, 26].  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 ***Wellbeing questionnaire***

25  
26 The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing,  
27 including attachment (love and friendship); security (thinking about the future without  
28 concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure);  
29 and control (independence),[27]. It has four-level response options, representing four levels of  
30 capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were  
31 transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full  
32 capability), and presented with mean and SDs using UK population weights,[3].  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 ***Quantitative variables***

46 The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were  
47 treated as continuous, while patients' sex, treatment type (dialysis, conservative care),  
48 education (some high school or lower levels, completed high school or higher levels), private  
49 health insurance (yes, no), and health system (UK, Australia) were analysed as categorical  
50 variables. Age was also additionally dichotomised (less than or equal to, versus greater than  
51 the median age [81 years]).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### ***Statistical methods***

The analysis of data involved descriptive statistics assessing proportions and mean values of the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease, Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort. Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients' treatment type and socio-demographic characteristics. We hypothesised that HRQoL and wellbeing measures in each treatment group would be equivalent.

Linear regression with multivariable models was undertaken to determine the association between treatment type and patient characteristics on SF-6D utilities, KDQOL scores and ICECAP-O capability index. In the multivariable linear regression, age, sex, treatment type, education, private health insurance, and health system were included as covariates on the basis of *a priori* knowledge of their associations with the HRQoL and wellbeing measures.

Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-O wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong positive correlations because both these instruments measures some similar facets of quality of life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and below 0.3 as weak,[16].



1  
2  
3 Complete case analysis was performed for all outcomes. All statistical analyses were performed  
4  
5 with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of  $<0.05$  was considered  
6  
7 statistically significant.  
8  
9

## 10 11 12 13 **RESULTS**

14  
15 A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%)  
16  
17 patients managed with comprehensive conservative care. The majority of conservatively  
18  
19 treated patients were from Australia ( $n = 37$ ), and most treated with dialysis were from the UK  
20  
21 ( $n = 58$ ). Overall, 65% were male, and the median age of the entire cohort was 81 years [IQR  
22  
23 78–85]. Patient characteristics are shown in Table 1.  
24  
25

### 26 27 28 *Health-related quality of life SF-6D utilities*

29  
30 Of 129 patients, the mean utility for 116 patients with complete data was 0.62 (SD 0.14) ( $n = 13$   
31  
32 missing values). The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65  
33  
34 (SD 0.15) for the conservative care group (Table S1). The “vitality” domain reported the  
35  
36 highest average score, and was responsible for the highest decrement in utilities in both  
37  
38 treatment groups (Table S2).  
39  
40  
41

42  
43  
44 The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males ( $p = 0.006$ );  
45  
46 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia  
47  
48 ( $p = 0.03$ ); and 0.07 (SD 0.14) lower for patients without a private health insurance compared  
49  
50 to patients with a private health insurance ( $p = 0.03$ ) (Table S1). When adjusted for all  
51  
52 variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower  
53  
54 CI = -0.14 and upper CI = -0.03,  $p = 0.002$ ). There was no significant difference in the mean  
55  
56 utilities observed between two treatments when adjusted for other variables (Table 2).  
57  
58  
59  
60

### KDQOL scores

The mean KDQOL scores on the five domains for patients with complete data were as follows: PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD 22.35).

In univariate analysis the PCS score was 5.46 points lower in females than males (p = 0.004) (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK patients (p = 0.03) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney Disease score was 28.12 points lower in the dialysis group than the conservative care group (p < 0.001) (indicating a higher burden of disease and lower quality of life) (Figure 1 and Figure 2); 14.06 points lower in UK versus Australian patients (p = 0.01) (indicating higher burden of disease); 13.70 points lower in patients without private health insurance compared to those with private health insurance (p = 0.04) (indicating a higher burden of disease). The Effects of Kidney Disease score was 17.11 points lower in the dialysis group compared to the conservative care group (p < 0.001) (indicating higher effects of the disease and lower quality of life) (Figure 3, Figure 4); 8.35 points lower in UK versus Australian patients (p = 0.03) (indicating higher effects of the disease).

The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better mental health than the conservative care group. (Table S2).

1  
2  
3 When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale  
4 was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on  
5 conservative care ( $p<0.001$ ) (Table 2). The mean score for Effects of Kidney Disease when  
6 adjusted for all the other variables, was 16.49 lower (i.e. higher disease related effects) for  
7 patients on dialysis compared with patients on comprehensive conservative care ( $p<0.001$ )  
8 (Table 2). Adjusted scores were lower but not statistically, significantly different for PCS, MCS  
9 and Symptoms of Kidney Disease between the two treatment groups.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 ***ICECAP-O capability index***

23  
24 The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19)  
25 (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and  
26 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different.  
27  
28 Overall, the dialysis treatment group reported a lower wellbeing score on all five domains  
29 compared to the conservative care group. The “attachment” domain showed the highest average  
30 score, and was responsible for the highest contribution to capabilities in both treatment groups  
31 (Table S2). When adjusted for other variables, there were no significant differences in the mean  
32 capability index observed between the two treatments (Table 2).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 ***Convergent validity***

46  
47 For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly  
48 correlated with the overall ICECAP-O capability index with a Pearson’s coefficient of 0.65  
49 ( $p<0.001$ ) and 0.56 ( $p<0.001$ ) respectively. At the domain level, the role and control domains  
50 of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D,  
51 with a Pearson’s coefficient of 0.51 ( $p<0.001$ ) and 0.53 ( $p<0.001$ ) respectively. All other  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values  
4  
5 ranging from 0.02 to 0.49 (Table 3).  
6  
7  
8  
9

### 10 **Feasibility and acceptability**

11  
12 115 of 129 patients completed the questionnaire, with 14 patients missing items for the  
13  
14 ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both  
15  
16 questionnaires easy to use and relevant to assessing their wellbeing. They responded with an  
17  
18 average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions  
19  
20 assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions  
21  
22 assessing the relevance of ICECAP-O and the SF-12 questions respectively.  
23  
24  
25  
26  
27  
28

## 29 **DISCUSSION**

30  
31 This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores  
32  
33 and ICECAP-O capability index for patients with ESKD according to treatment, and socio-  
34  
35 demographic variables. Our findings suggest females compared with males, patients residing  
36  
37 in the UK compared with those residing in Australia, and patients without private health  
38  
39 insurance compared with those with private health insurance have significantly lower SF-6D  
40  
41 utilities. However, when adjusted for the other variables, only females reported significantly  
42  
43 lower utilities compared with males. Furthermore, the study determined the convergent validity  
44  
45 between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility  
46  
47 and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with  
48  
49  
50  
51  
52 ESKD.  
53  
54  
55

56  
57 The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care  
58  
59 group reflecting a potentially clinically meaningful difference related to treatment, however,  
60

1  
2  
3 this difference was not statistically significant. Meaningful differences or the minimal  
4 important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D  
5 utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[28]. It is therefore likely our  
6 study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O  
7 wellbeing for dialysis patients may also represent a clinically meaningful difference, however,  
8 MIDs for ICECAP-O have not yet been published. Similarly, the KDQOL-36™ instrument  
9 identified a higher burden of disease, and greater effects of the disease for those on dialysis.  
10 This finding needs to be explored further in a larger sample size to investigate the potential  
11 detrimental effects of dialysis on HRQoL.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 In our study, with the exception of a strong correlation between the “control” and “role”  
27 domain of the ICECAP-O with the “pain” domain on the SF-6D, most of the ICECAP-O  
28 domains were found to have weak to moderate correlations with the SF-6D corresponding  
29 domains. This indicates the newly developed capability instrument does measure different  
30 aspects of quality of life or wellbeing, and offers additional information when compared to  
31 measures of health, such as the SF-6D used in the conventional QALY approach. In addition,  
32 we observed a higher score for the feasibility and acceptability of the ICECAP-O questions  
33 indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 There is debate in the health economics literature concerning the ways to apply the capability  
48 approach in economic evaluations with some suggesting that QALYs alone are adequate, while  
49 others argue this approach is too narrow, and that direct measures of capability or wellbeing  
50 provide a more extensive application of Sen’s paradigm,[29]. Capability is empirically distinct  
51 from functioning and the content of capability instruments is not subsumed by the content of  
52 instruments used to capture changes in HRQoL for QALYs,[29].  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Health economic analyses would benefit from the inclusion of individual capability measures;  
7  
8 whether the focus should be only upon people's *achievements*—their “functioning”—or  
9  
10 people's *capability to achieve* is contested,[29]. Sen's example of the fasting man versus the  
11  
12 starving man serves as a key example for focusing on capability: two people, one of whom is  
13  
14 starving and the other, who is fasting, have comparable functioning in terms of nourishment,  
15  
16 but their capabilities to be nourished are notably different,[29]. The argument is that focusing  
17  
18 on functioning alone would miss important distinctions, such as differences in freedom and  
19  
20 choice between individuals,[29].  
21  
22  
23  
24  
25

26 There are some limitations to this study. First, we were only able to recruit 129 of the 194  
27  
28 patients outlined in the protocol sample size, as some of the study sites were unable to  
29  
30 participate. Hence, the sample size may not have been sufficient to detect a statistically  
31  
32 significant difference in mean scores if one existed. Second, our observational study of older  
33  
34 patients with end-stage kidney disease may not have perfectly matched the two groups with  
35  
36 respect to co-morbid conditions or rate of renal decline. We did not have complete data on  
37  
38 comorbidities and this may have impacted our ability to explore the associations between  
39  
40 treatment type, HRQoL or wellbeing. Third, considering the cross-sectional nature of the data,  
41  
42 we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time,  
43  
44 which might be captured in a longitudinal study. The strengths of our study include a  
45  
46 prospective assessment of HRQoL in people over 75 years of age, and the use of a novel  
47  
48 measure to value wellbeing. This information is essential for doctors to discuss the relative  
49  
50 benefits of dialysis compared with conservative care.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD  
4 managed on dialysis compared to comprehensive conservative care. Furthermore, measuring  
5 wellbeing using a capability index provides additional insights into the impact of dialysis on  
6 older people than HRQoL measurement alone and has potential to improve the economic  
7 evaluation of treatment for ESKD.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

## Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

## Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

## Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

## Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the



1  
2  
3 UK. Each renal unit participating in the study obtained the approval of the Institutional Health  
4  
5 Research Ethics Committee to conduct the study. The study approval numbers are as follow:  
6  
7 UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203  
8  
9 HREC/14/RAH/36).  
10  
11  
12  
13

#### 14 **Data sharing statement**

15  
16  
17 Data for the study can be provided for specific research questions that are available from the  
18  
19 corresponding author on request.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. *Am J Kidney Dis.* 2012;59(3):419-27.
2. Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. *Clin J Am Soc Nephrol.* 2016;11(10):1909-14.
3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. *Soc Sci Med.* 2008;67(5):874-82.
4. Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. *PLoS One.* 2014;9(3):e92016.
5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. *Value Health.* 2009;12:S5-S9.
6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull.* 2010;96(1):5-21.
7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. *Hemodialysis International.* 2016;20(4):634-42.
8. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. *Nephrol Dial Transplant.* 2007;22(7):1955-62.
9. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care.* 1996;34(3):220-33.
10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. *Am J Kidney Dis.* 2016;67(6):820-1.
11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. *Soc Indic Res.* 1-16.
12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. *Qual Life Res.* 2012;21(1):167-76.
13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. *Soc Sci Med.* 2008;67(7):1190-8.
14. Sen A. Choice, welfare, and measurement: Harvard University Press; 1997.
15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? *Soc Sci Med.* 2006;62(8):1891-901.
16. Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. *Health Qual Life Outcomes.* 2013;11(1):57.
17. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLoS Med.* 2007;4(10):e297.
18. Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. *Am J Kidney Dis.* 2018;71(2):216-24.
19. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. *Nephrol Dial Transplant.* 2015;31(1):133-41.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. *Nephrol Dial Transplant*. 2011;26(12):4038-46.
21. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. *Am J Kidney Dis*. 2018;71(4):461-8.
22. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. *Med Care*. 2004;42(9):851-9.
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ*. 2002;21(2):271-92.
24. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. *J Health Econ*. 2007;26(3):597-612.
25. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental health summary scales: Health Institute, New England Medical Center; 1995.
26. Hays R, Spritzer K. KDQOL-36™ Scoring Program (v1. 0). 2000.
27. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. *Appl Health Econ Health Policy*. 2011;9(5):317-29.
28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res*. 2005;14(6):1523-32.
29. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? *Pharmacoeconomics*. 2017;35(6):637-46.

**Table 1: Patients characteristics according to treatment group**

Patient Characteristics	Dialysis	Conservative Care	Total
	n = 83 n (%)	n = 46 n (%)	n = 129 n (%)
<b>Dialysis</b>			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
<b>Median age (y)</b>	81 [78-84]	83 [81-87]	81 [78-85]
<b>Age group</b>			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
<b>Sex</b>			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
<b>Country</b>			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
<b>Education</b>			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
<b>Private Health Insurance</b>			
Yes	15 (18%)	14 (30%)	29 (22%)
No	65 (78%)	29 (63%)	94 (73%)
Unknown	1 (1%)	1 (2%)	2 (2%)

**Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)**

	Differences†	95 % Lower CI	95 % Upper CI	p value
<b>SF-6D utilities</b>	-0.05	-0.12	0.01	0.12
<b>KDQOL-PCS</b>	-3.17	-7.61	1.27	0.16
<b>KDQOL-MCS</b>	-2.41	-7.66	2.84	0.37
<b>KDQOL-Burden of Disease</b>	-28.59	-41.77	-15.42	<0.001*
<b>KDQOL-Symptoms of Disease</b>	-5.93	-14.61	2.73	0.18
<b>KDQOL-Effects of Disease</b>	-16.49	-25.98	-6.99	<0.001*
<b>ICECAP-O capability index</b>	-0.07	-0.16	0.02	0.12

† Difference in scores adjusted for age, gender, country, education, and health insurance status. \*  $p < 0.001$ , statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS -Mental Component Summary.

**Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)† using Pearson's correlation coefficient**

	ICECAP-O overall	ICECAP-O domain				
		Attachment	Security	Role	Enjoyment	Control
<b>SF-6D overall</b>	0.65**	-	-	-	-	-
<b>SF-6D domain</b>						
<b>Physical health</b>	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
<b>Role limitations</b>	0.30*	0.05	0.21*	0.28*	0.14	0.31*
<b>Social functioning</b>	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
<b>Pain</b>	<b>0.56**</b>	0.17	0.29*	<b>0.51**</b>	0.43**	<b>0.53**</b>
<b>Mental health</b>	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
<b>Vitality</b>	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

† Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). \* p < 0.05, statistical significance. \*\* p < 0.001, statistical significance.

## Figure Legends

**Figure 1-** Title: KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83).

*Explanatory text:* A higher score indicates lower burden of disease and better quality of life.

**Figure 2-** Title: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44).

*Explanatory text:* A higher score indicates lower burden of disease and better quality of life.

**Figure 3-** Title: KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82).

*Explanatory text:* A higher score indicates lower effects of disease and better quality of life.

**Figure 4-** Title: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45).

*Explanatory text:* A higher score indicates lower effects of disease and better quality of life.

1  
2  
3 **Supplementary Material**  
4  
5

6 **Supplementary Table 1 (Table S1):** SF-6D utilities, SF-12 PCS and MCS scores, and  
7  
8 ICECAP-O capability index according to patient characteristics  
9

10 **Supplementary Table 2 (Table S2):** Mean scores and weights of SF-6D, KDQOL-36 and  
11  
12 ICECAP-O according to treatment group  
13

14 **Supplementary Table 3 (Table S3):** KDQOL-36 Burden of Kidney Disease, Symptoms of  
15  
16 Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics  
17  
18

19 **Supplementary Item 1 (Item S1):** STROBE Statement: checklist of items that should be  
20  
21 included in reports of observational studies  
22  
23

24 **Supplementary Item 2 (Item S2):** KDQOL-36 Questionnaire (SF-12: Questions 1 – 12  
25  
26 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden  
27  
28 of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms  
29  
30 of kidney disease: Questions 29 – 36)  
31  
32

33 **Supplementary Item 3 (Item S3):** ICECAP-O Questionnaire  
34

35 **Supplementary Item 4 (Item S4):** Background Questions  
36  
37

38 **Supplementary Item 5 (Item S5):** SF-6D domains  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 1: KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83). A higher score indicates lower burden of disease and better quality of life.

84x63mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44). A higher score indicates lower burden of disease and better quality of life.

80x60mm (300 x 300 DPI)




Figure 3: KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82). A higher score indicates lower effects of disease and better quality of life.

84x63mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45). A higher score indicates lower effects of disease and better quality of life.

84x63mm (300 x 300 DPI)

Characteristics	SF-6D (n = 116) <sup>†</sup>	PCS (n = 115) <sup>††</sup>	MCS (n = 115) <sup>‡</sup>	ICECAP-O (n = 126) <sup>‡‡</sup>
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
<b>Age</b>				
≤81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)
<b>Gender</b>				
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)
Females	0.58 (0.53-0.62)*	28.85 (26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)
<b>Treatment**</b>				
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)
<b>Country</b>				
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)
Australia	0.65 (0.61-0.69)*	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68-0.79)
<b>Education §</b>				
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76)
Completed high school or tertiary education	0.63 (0.58-0.69)	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)
<b>Private Health Insurance ¶</b>				
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)
No/Unknown	0.61 (0.58-0.64)*	32.25 (30.09-34.40)	46.77 (44.40-49.13)	0.71 (0.67-0.75)

† Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. †† 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡ 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡‡ 3 out of 129 observations had missing values on SF-12 questionnaire and their capabilities index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Completed high school" and the responses to GCSEs/Completed high school/Diploma/A-level/Completed A-levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and ICECAP-O according to treatment group

Instrument	Score		Weights	
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
<b>SF-6D</b> ‡				
Physical functioning	2.47 (1.04)	2.26 (0.68)	-0.02 (0.02)	-0.018 (0.02)
Role limitations	3.22 (1.44)	2.84 (1.28)	-0.06 (0.02)	-0.05 (0.03)
Social functioning	3.33 (1.62)	2.65 (1.25)	-0.06 (0.03)	-0.06 (0.03)
Pain	3.29 (2.13)	2.60 (1.37)	-0.05 (0.05)	-0.04 (0.05)
Mental health	2.90 (1.92)	2.33 (1.10)	-0.05 (0.04)	-0.05 (0.04)
Vitality	3.86 (1.72)	3.57 (1.13)	-0.09 (0.02)	-0.09 (0.01)
<b>KDQOL-36</b>				
Physical Component Summary (PCS)	31.22 (9.32)	34.32 (10.05)	-	-
Mental Component Summary (MCS)	47.67 (11.12)	46.56 (11.78)	-	-
Burden of Kidney Disease	34.71 (27.77)	62.83 (29.45)	-	-
Symptom of Kidney Disease	70.71 (18.74)	76.61 (19.18)	-	-
Effects of Kidney Disease	64.18 (20.27)	81.29 (21.92)	-	-
<b>ICECAP-O</b> ‡‡				
Attachment (love and friendship)	3.25 (0.87)	3.27 (0.81)	0.22 (0.06)	0.22 (0.05)
Security (thinking about future without concern)	2.42 (0.99)	2.71 (0.92)	0.09 (0.05)	0.10 (0.05)
Role (doing things that make you feel valued)	2.51 (0.82)	2.69 (0.85)	0.15 (0.04)	0.15 (0.05)
Enjoyment (enjoyment and pleasure)	2.52 (0.94)	2.80 (0.97)	0.13 (0.04)	0.14 (0.04)
Control (independence)	2.51 (0.94)	2.82 (1.01)	0.13 (0.08)	0.15 (0.09)

‡ 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score; 1 observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease score; 1 observation missing value on all ICECAP-O domains. ‡ SF-6D domain scores are weighted decrements. ‡‡ ICECAP-O domain scores are weighted increments. SD - Standard deviation. KDQOL-36 - Kidney disease quality of life with 36 items.

Characteristics	Burden of Kidney Disease (n = 127) <sup>†</sup>	Symptoms of Kidney Disease (n = 125) <sup>††</sup>	Effects of Kidney Disease (n = 127) <sup>‡</sup>
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
<b>Age</b>			
≤81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
<b>Gender</b>			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
<b>Treatment**</b>			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 (59.72-68.63)*
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
<b>Country</b>			
United Kingdom	37.81 (30.68-44.94)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
<b>Education§</b>			
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary education	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
<b>Private Health Insurance¶</b>			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)

<sup>†</sup> 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>††</sup> 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. <sup>‡</sup> 2 out of 129 observations had missing values on effects of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. \* p < 0.05, statistical significance. \*\* The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. KDOQI-36 - Kidney disease quality of life with 36 items.

**Supplementary Item 1 (Item S1): STROBE Statement:** checklist of items that should be included in reports of observational studies

	<b>Item No</b>	<b>Recommendation</b>	<b>Yes/No/NA, Page No.</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Yes, page 1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes, Page 2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes, Page 4-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	Yes, Page 7
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Yes, Page 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Yes, Page 7-8
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes, Page 7-8



Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Yes, Page 8-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Yes, Page 9-10
Bias	9	Describe any efforts to address potential sources of bias	Yes, Page 8
Study size	10	Explain how the study size was arrived at	Yes, Protocol Page 7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Yes, Page 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Yes, Page 10-11
		(b) Describe any methods used to examine subgroups and interactions	Yes, Page 10-11
		(c) Explain how missing data were addressed	Yes, Page 10-11
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA

		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study— e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	No – screening logs at each site were not available
		(b) Give reasons for non-participation at each stage	No
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	Yes, Page 7-8, 22
		(b) Indicate number of participants with missing data for each variable of interest	Yes, Page 12-14, 24
		(c) <i>Cohort study</i> —Summarise follow-up time (e.g., average and total amount)	NA
Outcome data	15*	<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Yes, Page 11-14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Yes, Page 11-14, 23- 24

		(b) Report category boundaries when continuous variables were categorised	Yes, Page 11-14, 23-24
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	Yes, Page 11-14
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Yes, Page 15-16
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Yes, Page 17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Yes, Page 17
Generalisability	21	Discuss the generalisability (external validity) of the study results	Yes, Page 17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Yes, Page 18

1  
2  
3 **Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12**  
4  
5 **(converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden**  
6  
7 **of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms**  
8  
9 **of kidney disease: Questions 29 – 36)**  
10  
11  
12  
13  
14  
15  
16  
17  
18

---

# Your Health – and – Well-Being

## Kidney Disease and Quality of Life (KDQOL™-36)

19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.



*Thank you for completing these questions!*

---

Kidney Disease and Quality of Life™ (KDQOL™-36)  
English Version 1.  
Copyright © 2000 by RAND and the University of Arizona

# Your Health

**This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.**

**1. In general, would you say your health is: [Mark an  in the one box that best describes your answer.]**

Excellent	Very good	Good	Fair	Poor
<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5

**The following items are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much? [Mark an  in a box on each line.]**

Yes, limited a lot	Yes, limited a little	No, not limited at all
--------------------------	-----------------------------	------------------------------

- 2. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf .....**  1.....  2.....  3
- 3. Climbing several flights of stairs .....**  1.....  2.....  3

1  
2  
3  
4 **During the past 4 weeks, have you had any of the following problems**  
5 **with your work or other regular daily activities as a result of your**  
6 **physical health?**  
7

8  
9 

Yes	No
-----	----

10  
11  
12  
13 4. Accomplished less than you would like.....  1..... 2

14  
15  
16 5. Were limited in the kind of work or other  
17 activities .....  1..... 2

18  
19  
20  
21  
22  
23 **During the past 4 weeks, have you had any of the following problems**  
24 **with your work or other regular daily activities as a result of any**  
25 **emotional problems (such as feeling depressed or anxious)?**  
26

27 

Yes	No
-----	----

28  
29  
30  
31  
32 6. Accomplished less than you would like.....  1..... 2

33  
34  
35 7. Didn't do work or other activities as carefully as  
36 usual .....  1..... 2

37  
38  
39  
40  
41  
42 **8. During the past 4 weeks, how much did pain interfere with your**  
43 **normal work (including both work outside the home and**  
44 **housework)?**  
45

46 

Not at all	A little bit	Moderately	Quite a bit	Extremely
------------	--------------	------------	-------------	-----------

47  
48  
49  
50  1       2       3       4       5

**These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please give the one answer that comes closest to the way you have been feeling.**

**How much of the time during the past 4 weeks ...**

		A good			
All	Most	bit	Some	A little	None
of the	of the	of the	of the	of the	of the
time	time	time	time	time	time

9. Have you felt calm and peaceful? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6
10. Did you have a lot of energy? .....  1 .....  2 .....  3 .....  4 .....  5 .....  6
11. Have you felt downhearted and blue? .  1 .....  2 .....  3 .....  4 .....  5 .....  6

**12. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)?**

All	Most	Some	A little	None
of the time	of the time	of the time	of the time	of the time
<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3	<input type="checkbox"/> 4	<input type="checkbox"/> 5

## Your Kidney Disease

How true or false is each of the following statements for you?

Definitely true	Mostly true	Don't know	Mostly false	Definitely false
--------------------	----------------	---------------	-----------------	---------------------

13. My kidney disease interferes too much with my life .....  1 .....  2 .....  3 .....  4 .....  5
14. Too much of my time is spent dealing with my kidney disease .....  1 .....  2 .....  3 .....  4 .....  5
15. I feel frustrated dealing with my kidney disease .....  1 .....  2 .....  3 .....  4 .....  5
16. I feel like a burden on my family .....  1 .....  2 .....  3 .....  4 .....  5

www only



**During the past 4 weeks, to what extent were you bothered by each of the following?**

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

- 17. Soreness in your muscles? .....  1 .....  2 .....  3 .....  4 .....  5
- 18. Chest pain? .....  1 .....  2 .....  3 .....  4 .....  5
- 19. Cramps? .....  1 .....  2 .....  3 .....  4 .....  5
- 20. Itchy skin?.....  1 .....  2 .....  3 .....  4 .....  5
- 21. Dry skin?.....  1 .....  2 .....  3 .....  4 .....  5
- 22. Shortness of breath?.....  1 .....  2 .....  3 .....  4 .....  5
- 23. Faintness or dizziness?.....  1 .....  2 .....  3 .....  4 .....  5
- 24. Lack of appetite? ...  1 .....  2 .....  3 .....  4 .....  5
- 25. Washed out or drained?.....  1 .....  2 .....  3 .....  4 .....  5
- 26. Numbness in hands or feet?.....  1 .....  2 .....  3 .....  4 .....  5
- 27. Nausea or upset stomach?.....  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>a</sup>. (Hemodialysis patient only)  
Problems with your access site? ...  1 .....  2 .....  3 .....  4 .....  5
- 28<sup>b</sup>. (Peritoneal dialysis patient only)  
Problems with your catheter site?..  1 .....  2 .....  3 .....  4 .....  5

## Effects of Kidney Disease on Your Daily Life

Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease bother you in each of the following areas?

Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
------------------------	----------------------	------------------------	-----------------------	-----------------------

29. Fluid restriction?.....  1 .....  2 .....  3 .....  4 .....  5
30. Dietary restriction?.....  1 .....  2 .....  3 .....  4 .....  5
31. Your ability to work around the house? .....  1 .....  2 .....  3 .....  4 .....  5
32. Your ability to travel? .....  1 .....  2 .....  3 .....  4 .....  5
33. Being dependent on doctors and other medical staff?.....  1 .....  2 .....  3 .....  4 .....  5
34. Stress or worries caused by kidney disease? .....  1 .....  2 .....  3 .....  4 .....  5
35. Your sex life? .....  1 .....  2 .....  3 .....  4 .....  5
36. Your personal appearance? .....  1 .....  2 .....  3 .....  4 .....  5

**Supplementary Item 3 (Item S3): ICECAP-O Questionnaire**

**ABOUT YOUR QUALITY OF LIFE**

By placing a tick (✓) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.

**1. Love and Friendship**

I can have all of the love and friendship that I want	<input type="checkbox"/>	4
I can have a lot of the love and friendship that I want	<input type="checkbox"/>	3
I can have a little of the love and friendship that I want	<input type="checkbox"/>	2
I cannot have any of the love and friendship that I want	<input type="checkbox"/>	1

**2. Thinking about the future**

I can think about the future without any concern	<input type="checkbox"/>	4
I can think about the future with only a little concern	<input type="checkbox"/>	3
I can only think about the future with some concern	<input type="checkbox"/>	2
I can only think about the future with a lot of concern	<input type="checkbox"/>	1

**3. Doing things that make you feel valued**

I am able to do all of the things that make me feel valued	<input type="checkbox"/>	4
I am able to do many of the things that make me feel valued	<input type="checkbox"/>	3
I am able to do a few of the things that make me feel valued	<input type="checkbox"/>	2
I am unable to do any of the things that make me feel valued	<input type="checkbox"/>	1

**4. Enjoyment and pleasure**

I can have all of the enjoyment and pleasure that I want	<input type="checkbox"/>	4
I can have a lot of the enjoyment and pleasure that I want	<input type="checkbox"/>	3
I can have a little of the enjoyment and pleasure that I want	<input type="checkbox"/>	2
I cannot have any of the enjoyment and pleasure that I want	<input type="checkbox"/>	1

**5. Independence**

I am able to be completely independent	<input type="checkbox"/>	4
I am able to be independent in many things	<input type="checkbox"/>	3
I am able to be independent in a few things	<input type="checkbox"/>	2
I am unable to be at all independent	<input type="checkbox"/>	1

Tick  
one  
box  
only in  
each  
section

© Joanna Coast & Terry Flynn

**Supplementary Item 4 (Item S4): Background Questions**

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Q1. What is your full name? \_\_\_\_\_
- Q2. What is your date of birth? \_\_\_\_\_ (dd/mm/yyyy)
- Q3. Gender (*please tick one*)
- Male
- Female
- Q4. What is your main residential postcode? \_\_\_\_\_
- Q5. What was your country of birth? \_\_\_\_\_
- Q6. What is the highest level of education you have completed? (*please tick the box that best describes you*)
- Primary school
- Some high school
- Completed high school
- Completed Diploma/ TAFE course
- Completed University Degree
- Q7. Do you have private health insurance? (*please tick one*)
- Yes
- No
- Don't know
- Q8. What type of kidney treatment are you **currently** having? (*please tick one*)
- Hemodialysis (satellite or hospital)
- Hemodialysis at home
- Peritoneal dialysis
- Non-dialysis renal supportive care

Q9. If you are currently on dialysis when did you first start dialysis?

\_\_\_\_\_ (mm/yyyy)

Q10. Have you ever had a kidney transplant before? *(please tick one)*

Yes  No

Q11. The next two questions are about the **ICECAP-O survey**. On the scale below please rate how easy this survey was to complete *(circle a number between 1 and 5)*

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

Q12. Did this survey measure the things that you consider important to your quality of life? *(circle a number between 1 and 5)*

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

Q13. If you responded with ‘somewhat disagree’ or ‘completely disagree,’ would you like to tell us what you think the **ICECAP-O survey** was missing?

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

1  
2  
3 Q14. The next two questions are about the **SF-12 survey**. On the scale below please rate  
4  
5 how easy this survey was to complete (*circle a number between 1 and 5*)  
6  
7

Very easy	Somewhat easy	Neutral	Somewhat difficult	Very difficult
1	2	3	4	5

8  
9  
10  
11  
12  
13  
14  
15  
16  
17 Q15. Did this survey measure the things that you consider important to your quality  
18  
19 of life? (*circle a number between 1 and 5*)  
20  
21

Completely agree	Somewhat agree	Neutral	Somewhat disagree	Completely disagree
1	2	3	4	5

22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would  
32  
33 you like to tell us what you think the **SF-12 survey** was missing?  
34  
35

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---



---



---



---

## Supplementary Item 5 (Item S5): SF-6D domains

Level	SF-6D
	<i>Physical Functioning</i>
1	Your health does not limit you in <i>vigorous activities</i>
2	Your health limits you a little in <i>vigorous activities</i>
3	Your health limits you a little in <i>moderate activities</i>
4	Your health limits you a lot in <i>moderate activities</i>
5	Your health limits you <i>a little in bathing and dressing</i>
6	Your health limits you <i>a lot in bathing and dressing</i>
	<i>Role limitations</i>
1	You have <i>no</i> problems with your work or other regular daily activities as a result of your physical health or any emotional problems
2	You are limited in the kind of work or other activities as a result of your physical health
3	You accomplish less than you would like as a result of emotional problems
4	You are limited in the kind of work or other activities as a result of your physical health and accomplish less than you would like as a result of emotional problems
	<i>Social functioning</i>
1	Your health limits your social activities <i>none of the time</i>
2	Your health limits your social activities <i>a little of the time</i>
3	Your health limits your social activities <i>some of the time</i>
4	Your health limits your social activities <i>most of the time</i>
5	Your health limits your social activities <i>all of the time</i>
	<i>Pain</i>
1	You have <i>no</i> pain
2	You have pain but it does not interfere with your normal work (both outside the home and housework)
3	You have pain that interferes with your normal work (both outside the home and housework) <i>a little bit</i>
4	You have pain that interferes with your normal work (both outside the home and housework) <i>moderately</i>
5	You have pain that interferes with your normal work (both outside the home and housework) <i>quite a bit</i>
6	You have pain that interferes with your normal work (both outside the home and housework) <i>extremely</i>
	<i>Mental health</i>
1	You feel tense or downhearted and low <i>none of the time</i>
2	You feel tense or downhearted and low <i>a little of the time</i>
3	You feel tense or downhearted and low <i>some of the time</i>
4	You feel tense or downhearted and low <i>most of the time</i>
5	You feel tense or downhearted and low <i>all of the time</i>
	<i>Vitality</i>
1	You have a lot of energy <i>all of the time</i>
2	You have a lot of energy <i>most of the time</i>
3	You have a lot of energy <i>some of the time</i>
4	You have a lot of energy <i>a little of the time</i>
5	You have a lot of energy <i>none of the time</i>

Copyright © 2004 John Wiley & Sons, Ltd.